Front. Mol. Neurosci. Frontiers in Molecular Neuroscience Front. Mol. Neurosci. 1662-5099 Frontiers Media S.A. 10.3389/fnmol.2025.1625943 Molecular Neuroscience Review Exosome-mediated miRNA delivery: a molecular switch for reshaping neuropathic pain therapy Wei Ziqing 1 2 ‡ † Guo Chunhui 1 2 ‡ † Zhou Hang 1 2 ‡ Wu Yanling 1 2 ‡ Zhou Xudong 3 Chen Jibing 2 * ‡ Li Fujun 4 * ‡ 1Graduate School, Guangxi University of Chinese Medicine, Nanning, China 2Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China 3Graduate School, Guangxi University, Nanning, China 4Zhuhai Maternal and Child Health Care Hospital, (Guangxi University of Chinese Medicine), Zhuhai, China

Edited by: Lei Yu, Rutgers, The State University of New Jersey, United States

Reviewed by: Parisa Gazerani, Oslo Metropolitan University, Norway

Paramita Basu, University of Pittsburgh, United States

 *Correspondence: Jibing Chen, jibingchen398@163.com; Fujun Li, lfjyyq@163.com

‡ORCID: Ziqing Wei, orcid.org/0009-0000-7931-3226

Chunhui Guo, orcid.org/0009-0000-3751-6420

Hang Zhou,orcid.org/0009-0006-7067-5435

Yanling Wu, orcid.org/0009-0001-6302-8487

Jibing Chen, orcid.org/0000-0001-8596-2126

Fujun Li, orcid.org/0009-0001-9837-3678

†These authors have contributed equally to this work

 04 07 2025 21 08 2025 2025 18 1625943 09 05 2025 19 06 2025 Copyright © 2025 Wei, Guo, Zhou, Wu, Zhou, Chen and Li. 2025 Wei, Guo, Zhou, Wu, Zhou, Chen and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Neuropathic pain (NP) is a chronic condition caused by nerve injury or disease. It remains a therapeutic challenge because conventional drugs have limited efficacy and cause adverse effects. Exosomes, with the ability to cross the blood-brain barrier, low immunogenicity, and tissue-homing capacity, have emerged as promising nanovehicles for precise microRNA (miRNA) delivery to modulate key NP pathologies such as neuroinflammation, neuronal hyperexcitability, mechanical allodynia, and thermal hyperalgesia. In this review, we highlight recent advances in exosome-mediated miRNA therapy for NP. We also elucidate the molecular mechanisms and unique advantages of exosomes as both delivery platforms and intrinsic therapeutic agents. We synthesize evidence from preclinical models and initial clinical-stage studies, addressing translational challenges in scalable production and targeted delivery. Through sustained innovation and multidisciplinary collaboration, exosome-based miRNA delivery systems demonstrate transformative potential to overcome current therapeutic limitations, enabling novel NP management strategies.

 neuropathic pain targeted delivery miRNA therapeutics exosomes pain management clinical translation 82460874 2024GXNSFAA01035 Guike AB25069271 2025GXNSFAA0691007 Regional Fund Project of the National Natural Science Foundation of China General Program of Guangxi Natural Science Foundation Key Research and Development Program of Guangxi General Program of Guangxi Natural Science Foundation section-at-acceptance Pain Mechanisms and Modulators Introduction

Neuropathic pain (NP) constitutes a debilitating chronic condition originating from lesions or diseases affecting the somatosensory nervous system (Finnerup et al., 2021). Afflicting approximately 7% of the global population, it imposes substantial clinical, economic, and societal burdens (Savelieff et al., 2025). Patients typically experience characteristic manifestations including spontaneous burning sensations, electric shock-like pain, and mechanically evoked allodynia—paradoxical pain perception in response to non-noxious stimuli such as light touch. The pathophysiology involves multifaceted mechanisms encompassing peripheral and central sensitization (e.g., dysregulated ion channels, NMDA receptor activation), neuroinflammation (e.g., TLR4/NF-κB signaling in glial cells), and impaired neural repair (Vranken, 2012; Zhang et al., 2023; Kaye et al., 2024).

Current NP management primarily relies on pharmacological interventions (e.g., antidepressants, calcium channel modulators, topical anesthetics) (Alcántara-Montero and Pacheco-de Vasconcelos, 2022; Bayer et al., 2004; Moisset et al., 2022) and neuromodulation techniques [e.g., transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS)] (da Silva et al., 2024; Leung et al., 2020). However, these approaches face critical limitations: systemic adverse effects (sedation, anticholinergic effects), insufficient efficacy in subsets of patients, and inability to concurrently target multiple NP mechanisms. Compromised central nervous system bioavailability due to the blood-brain barrier (BBB) further restricts therapeutic effectiveness (Amescua-Garcia et al., 2018; Ardeleanu et al., 2020). Consequently, NP remains inadequately managed in many patients, underscoring the urgent need for novel multitargeted therapeutic strategies with enhanced central nervous system (CNS) delivery capabilities.

MicroRNAs (miRNAs), serving as pivotal post-transcriptional regulators in NP pathogenesis, modulate neuroinflammation, neuronal hyperexcitability, and nerve repair (Wang et al., 2024). Their capacity to concurrently fine-tune multiple target gene networks offers significant therapeutic advantages over single-target drugs (Chang et al., 2017; Peng et al., 2017). Nevertheless, clinical translation of miRNA therapies is hindered by rapid degradation, poor cellular uptake, and inefficient BBB penetration (Shityakov et al., 2022). Exosomes—natural nanoscale extracellular vesicles—provide a promising solution to these delivery challenges. They inherently protect cargo molecules (e.g., miRNAs) from degradation, exhibit low immunogenicity, possess intrinsic homing capacity toward injured tissues, and critically, traverse the BBB (Liu et al., 2024). Recent advances in exosome engineering further enhance their delivery potential (Nouri et al., 2024). Exosome-mediated miRNA delivery thus represents a transformative strategy to overcome limitations of conventional NP treatments through precision modulation of multiple pathological mechanisms. This review focuses on the emerging paradigm of exosome-mediated miRNA delivery for NP management. We outline the therapeutic rationale for miRNAs in NP pathogenesis and exosomes’ unique advantages as delivery vehicles, evaluate preclinical and clinical evidence for exosomal miRNA efficacy, and discuss clinical translation challenges and future directions.

 Methods

This narrative review synthesizes literature retrieved from electronic databases including PubMed and ClinicalTrials.gov using core search terms: “exosomes,” “microRNA,” “neuropathic pain,” and “miRNA pain therapy” with their English equivalents. Included studies fulfilled these criteria: (1) mechanistic validation in animal or cellular models, and (2) documented evidence of exosome-mediated miRNA delivery. Exclusion criteria comprised case reports and non-English publications.

miRNAs in NP pathogenesis Expression profiles and therapeutic potential

MicroRNAs (miRNAs) are endogenous small non-coding RNAs (approximately 22 nucleotides) that regulate gene expression by binding to the 3′ untranslated region (3′ UTR) of target mRNAs. This interaction, primarily mediated by a 6–8 nucleotide seed sequence, induces mRNA degradation or translational repression (Liu et al., 2025; Sun et al., 2017; Yang X. et al., 2023). Through this post-transcriptional regulation, miRNAs orchestrate critical cellular processes in NP pathogenesis, including neuroinflammation, neuronal hyperexcitability, and impaired nerve repair (Wilkerson et al., 2020). miRNA-mRNA network analysis identified multiple dysregulated miRNAs (e.g., miR-30c-5p, miR-16-5p) and their target genes (Rnase4, Egr2), revealing inflammation-associated regulatory mechanisms in NP (Cai et al., 2020). These findings support their potential as diagnostic biomarkers and therapeutic targets. Widespread miRNA alterations occur at key pain-processing sites [dorsal root ganglia (DRG) and spinal cord] across NP models [spared nerve injury (SNI), spinal nerve ligation (SNL), chronic constriction injury (CCI), and diabetic neuropathy]. Specific miRNAs including miR-21, miR-124, and miR-146a demonstrate significant dysregulation following nerve injury (Zhong et al., 2019; Zhang et al., 2019; Lv et al., 2017). Consistent with these observations, clinical studies report abnormal expression of miR-21, miR-146a, and miR-155 in sural nerves, skin biopsies, and circulating leukocytes from patients with painful peripheral neuropathy (Leinders et al., 2017). Mechanistically, these dysregulated miRNAs converge on three core pathways: neuroinflammatory signaling modulation (TLR4/NF-κB, NLRP3 inflammasome, cytokine release via TRAF6/IRAK1/STAT3 targeting), ion channel regulation (Nav1.7, TRPV1, Kv channels), and mediation of neuroimmune interactions and neural repair processes (Yan et al., 2017; Sun et al., 2021).

The extensive dysregulation of miRNAs establishes them as potent therapeutic targets for NP, offering three primary advantages:

Multi-target potential: Individual miRNAs regulate gene networks governing NP mechanisms (e.g., neuroinflammation, excitability), surpassing single-target drugs.

Mechanism-driven efficacy: Functional restoration of specific miRNAs (e.g., miR-146a-5p) using agomirs/antagomirs alleviates pain hypersensitivity and neuroinflammation in preclinical models (Wang et al., 2018).

Diagnostic and predictive biomarkers: Distinct miRNA expression patterns in biofluids or tissues (e.g., elevated serum hsa-miR-19a-3p and hsa-miR-19b-3p) enable NP subtype stratification, informing personalized therapies (Tavares-Ferreira et al., 2019).

 Core regulatory mechanisms Regulation of inflammatory cascades

Within NP pathology, miRNAs exert precise control over neuroimmune interactions by targeting critical signaling nodes: During inflammation initiation, Toll-like receptor (TLR) family members including TLR4 recognize damage-associated molecular patterns (DAMPs), activating the IRAK1/TRAF6 complex through MyD88-dependent pathways. This drives NF-κB/MAPK activation and progressive release of pro-inflammatory cytokines including TNF-α and IL-1β (Zarezadeh Mehrabadi et al., 2022). During inflammation amplification, miR-23a inhibits IL-1β maturation in microglia by dual-targeting CXCR4 (immune cell chemokine receptor) and TXNIP (key NLRP3 activation factor) (Pan et al., 2018). Concurrently, the CXCL12/CXCR4 axis recruits immune cells such as macrophages to infiltrate injury sites, exacerbating neuroinflammation (Liu et al., 2019), whereas miR-144 and miR-140 suppress this pathway (Li et al., 2021; Zhang et al., 2020a). Through negative feedback regulation, miR-146a-5p binds the 3′ UTR of TRAF6/IRAK1 mRNAs, establishing self-limiting control of NF-κB activation (Hou et al., 2021). Additionally, miRNAs modulate inflammatory cascades by targeting transcription factors: miR-136 and miR-128-3p inhibit ZEB1, blocking pro-inflammatory gene transcription (Bao et al., 2018; Shen et al., 2019; Yan et al., 2018; Zhang et al., 2020b). miR-363-5p targets SERPING1 (regulated by SP5), conferring dual analgesic/anti-inflammatory effects that SERPING1 overexpression negates (Wu et al., 2025). Collectively, miRNAs orchestrate multi-layered regulation of neuroinflammation, establishing them as potential therapeutic targets for NP.

 Regulation of ion channel homeostasis

Neuronal hyperexcitability constitutes a core feature of NP, primarily driven by dysfunctional ion channel expression and activity. Exosome-mediated miRNA delivery enables novel therapeutic strategies for targeting channelopathies in voltage-gated sodium (Nav), potassium (Kv), calcium (Cav), and transient receptor potential (TRP) channels. Abnormal Nav isoform activation including Nav1.3, Nav1.7, and Nav1.8 can be selectively regulated through miRNAs: miR-30b directly targets SCN3A mRNA (Su et al., 2017); miR-182 inhibits SCN9A translation (Cai et al., 2018); and miR-7a downregulates β2 subunit (SCN2B) expression (Sakai et al., 2013), collectively reducing ectopic discharges in DRG. In contrast, miR-3584-5p exacerbates chronic constriction injury pain through Nav1.8 current suppression (Yang R. et al., 2023). Voltage-gated potassium channels critically control neuronal excitability by governing action potential generation, firing frequency, and neurotransmitter release (Manville et al., 2018; Kim and Nimigean, 2016). The miR-17-92 cluster maintains mechanical hypersensitivity post-injury through coordinated Kv regulation. This cluster contains six members—miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a-that remain persistently upregulated in injured sensory neurons (Sakai et al., 2017). Dysregulation mechanisms include miR-19a-mediated Kv4.2/4.3 mRNA targeting that reduces A-type potassium currents, and miR-137-induced Kcna2 inhibition that decreases Kv1.2 expression, both elevating neuronal excitability and pain perception. miR-137 inhibition restores Kv1.2 expression, normalizes neuronal excitability, and alleviates pain (Zhang et al., 2021). In calcium channel regulation, miR-103 targets CACNB1/CACNA2D1 (Cav1.2 auxiliary subunits) (Favereaux et al., 2011) while miR-32-5p silences Cav3.2 through histone methylation (Qi et al., 2022), both reducing calcium influx to block nociceptive sensitization. TRP channel modulation involves miR-375 and miR-455 suppressing TRPV1 expression (Li Z. et al., 2022), whereas miR-141-5p alleviates oxaliplatin-induced NP by inhibiting TRPA1 expression, thereby reducing Ca2+ influx and neuronal excitability (Zhang and Chen, 2021).

 Neural regeneration and repair

Persistent NP following nerve injury may cause cellular damage or neuronal death in spinal cord and peripheral nerve tissues (Cohen et al., 2021). Recent studies reveal that injured peripheral neurons release endogenous neurotrophic factors including brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF), promoting neuronal survival and axonal regeneration (Keefe et al., 2017; Han and Xu, 2020). The bidirectional regulatory capacity of exosomal miRNAs offers unique therapeutic value for neural repair. Excessive glial scar formation impedes axonal regeneration. miRNAs balance pro-inflammatory and repair processes by targeting glial activation states: miR-503-5p alleviates NP in type 2 diabetes mellitus (T2DM) mice through suppressing SEPT9 expression in astrocytes, while miR-204 enhances sensory functional recovery by upregulating glial cell-derived neurotrophic factor (GDNF) in microglia (Guo et al., 2024; Shen et al., 2020). Concurrently, miRNAs directly regulate neuronal regeneration: miR-155 deficiency promotes axonal regeneration through enhanced SPRR1A expression (Gaudet et al., 2016), whereas miR-135a and miR-135b counteract regenerative inhibition by suppressing Kruppel-like factor 4 (KLF4) (van Battum et al., 2018). miR-210 inhibits apoptosis via ephrin-A3 (EFNA3) to support neuronal survival (Hu et al., 2016). Notably, certain miRNAs exhibit dual regulatory properties. For example, miR-21 promotes Schwann cell-mediated axonal regeneration by inhibiting EPHA4/TIMP3 (Ning et al., 2020), yet activates the epidermal growth factor receptor (EGFR) pathway to exacerbate glial scarring (Kar et al., 2021). Across various neural injury models, miR-21 demonstrates functional versatility by modulating multiple signaling pathways to promote neural repair (Ning et al., 2020; Kar et al., 2021; Li et al., 2018).

These findings demonstrate that miRNAs therapeutically target core NP mechanisms (Table 1). However, clinical translation faces challenges including nuclease-mediated degradation and inadequate targeting specificity (Pedder et al., 2025; Wang and Wu, 2024). Developing stable delivery systems for miRNA mimics/inhibitors remains a critical unmet need (Zhang et al., 2017).

Core mechanisms of miRNA targeted intervention in neuropathic pain.

Mechanism miRNA Model Target Effect Objective References
Neuroinflammation miR-23a↑ pSNL CXCR4/TXNIP/NLRP3↓ Ameliorates mechanical allodynia C57BL/6 mice Pan et al. (2018)
miR-140↑ CCI S1PR1↓ Ameliorates mechanical allodynia SD rats Li et al. (2021)
miR-144↑ CCI RASA1↓ Alleviates mechanical allodynia C57BL/6 mice Zhang et al. (2020a)
miR-146a-5p↑ CCI IRAK1/TRAF6↓ Suppresses mechanical allodynia and thermal hyperalgesia SD rats Hou et al. (2021)
miR-136↑ CCI ZEB1↓ Ameliorates mechanical allodynia SD rats Shen et al. (2019)
miR-128-3p↑ CCI ZEB1↓ Suppresses mechanical allodynia and thermal hyperalgesia SD rats Zhang et al. (2020b)
miR-363-5p↑ CCI SERPING1↓ Suppresses mechanical allodynia and thermal hyperalgesia SD rats Wu et al. (2025)
Neuronal ion channels miR-30b↑ SNL SCN3A (Nav1.3)↓ Attenuates NP SD rats Su et al. (2017)
miR-182↑ SNI SCN9A (Nav1.7)↓ Attenuates NP SD rats Cai et al. (2018)
miR-7a↑ CCI/SNL β2 subunit (SCN2B)↓ Attenuates NP SD rats Sakai et al. (2013)
miR-3584-5p↑ CCI ERK5/CREB (Nav1.8)↓ Aggravates NP; promotes apoptosis SD rats Yang R. et al. (2023)
miR-17-92↓ SNL Multiple voltage-gated K+ channels↑ Alleviate NP SD rats Sakai et al. (2017)
miR-137↓ CCI Kcna2 (Kv1.2)↑ Reduces tactile sensitivity; increases thermal sensitivity SD rats Zhang et al. (2021)
miR-103↑ SNL Cav1.2-LTC↓ Attenuates NP Wistar rats Favereaux et al. (2011)
miR-32-5p↑ CCI-ION Cav3.2↓ Attenuates NP SD rats Qi et al. (2022)
miR-141-5p↑ Oxaliplatin (OXA) TRPA1↓ Attenuates NP SD rats Zhang and Chen (2021)
Neural repair miR-503-5p↑ DPN SEPT9↓ Reduces astrocyte activation and ameliorates NP db/db mice Guo et al. (2024)
miR-155↓ SCI SPRR1A↑ Reduces inflammatory signaling; promotes neuronal survival and neurite growth C57BL/6 mice Gaudet et al. (2016)
miR-135a/b↑ ONI KLF4↓ Promotes axon regeneration C57BL/6 mice van Battum et al. (2018)
miR-21↑ SNL TGFβI/TIMP3/EPHA4↓ Facilitates SC proliferation and axon regeneration SD rats Ning et al. (2020)
miR-21↑ ONC EGFR↑ Facilitates axon regeneration SD rats Li et al. (2018)
miR-21↑ SNI PTEN↓ Facilitates axon regeneration SD rats Kar et al. (2021)

pSNL, partial sciatic nerve ligation; CCI, chronic constriction injury; SNL, spinal nerve ligation; SNI, spared nerve injury; SCI, spinal cord injury; DPN, diabetic peripheral neuropathy; ONI, optic nerve injury; CCI-ION, chronic constriction injury of infraorbital nerve; OXA, oxaliplatin (chemotherapy-induced neuropathy model); ↑, denotes miRNA overexpression intervention; ↓, indicates miRNA suppression intervention; Arrows (↑/↓), signify direction of target expression changes (e.g., NLRP3↓ = inflammasome suppression).

 Overview of exosomes Biological properties

Exosomes represent a subtype of extracellular vesicles (EVs) ranging from 50–150 nm in diameter. They are distinguishable from microvesicles (100–1,000 nm) by surface markers CD63/CD9 (Meldolesi, 2018). These vesicles form through bilayer invagination of cellular membranes and are subsequently released from multivesicular bodies (MVBs) (Yang et al., 2024). Though initially considered cellular waste disposal machinery, exosomes secreted by all cell types—including immune cells and neurons—are now recognized as crucial mediators of intercellular and intracellular communication. MVBs reside within cell bodies of DRG sensory neurons, which may release EVs (including exosomes) under appropriate conditions. Exosomes contain functionally diverse proteins essential for cell adhesion, membrane fusion, metabolism, and signal transduction. Beyond proteins, they carry multiple nucleic acids including miRNAs, messenger RNAs (mRNAs), DNA fragments, and long non-coding RNAs. These constituents mediate intercellular signaling in biological processes such as immune modulation and neural transmission (Bahram Sangani et al., 2021). Notably, exosomes are widely present in bodily fluids and transmit molecular signals via paracrine, autocrine, or endocrine pathways (Chen et al., 2019). Their biogenesis occurs in virtually all cell types (Habib et al., 2023), with particularly active production observed in tumor cells (Graner, 2019), immune cells, and neural cells. Emerging evidence indicates cellular origin critically determines both exosomal cargo composition and biological functionality (Yang et al., 2025). Substantial differences in contents, surface markers, and functions exist among exosomes derived from distinct cell types, suggesting specialized roles in biological processes.

 Biogenesis and secretion processes

Though several mechanisms of exosome biosynthesis and secretion have been identified, many aspects remain incompletely understood. Exosome formation constitutes a complex multistep process involving membrane budding, invagination, multivesicular body (MVB) formation, and ultimate secretion (Ren et al., 2024). Recent studies demonstrate that exosome generation primarily relies on the intraluminal vesicle (ILV) formation pathway (Ghosh et al., 2024), comprising both ESCRT-dependent and ESCRT-independent mechanisms (Bavafa et al., 2025). The ESCRT (endosomal sorting complexes required for transport) complexes drive ILV generation through membrane remodeling and cargo sorting (Larios et al., 2020). Specifically, the ESCRT-0 complex recognizes and recruits cargo proteins, while ESCRT-I and ESCRT-II collectively promote membrane invagination, and ESCRT-III mediates vesicle fission and release (Ju et al., 2021). Precise regulation of the ESCRT machinery is critical not only for ILV formation but also for exosome secretion (Horbay et al., 2022). Beyond ESCRT-dependent pathways, exosome biogenesis involves alternative mechanisms (Yang et al., 2024). Lipid molecules including ceramide play pivotal roles by altering membrane lipid composition, enhancing fluidity, and facilitating ILV generation (Yanagawa et al., 2024). Furthermore, phosphatidylinositol 3-kinase (PI3K) and its product phosphatidylinositol-3,4,5-trisphosphate (PIP3) significantly contribute to exosome production (Yao et al., 2025). Exosome trafficking and release constitute equally complex processes governed by molecular regulators such as Rab GTPases (e.g., Rab27a/b) (Kim et al., 2024). These GTPases regulate MVB-plasma membrane fusion to ensure precise exosome transport and secretion. Recipient cells internalize exosomes primarily through endocytosis, direct membrane fusion, or surface receptor interactions (Vučemilović, 2024). Though endocytosis represents the predominant mechanism, direct fusion offers greater therapeutic promise for drug delivery due to enhanced intracellular cargo release efficiency (Hushmandi et al., 2024). These discoveries deepen our understanding of exosome biogenesis while establishing theoretical foundations for novel therapeutic strategies.

 Advantages of exosomes as delivery vehicles Natural targeting capacity

The targeting capacity of exosomes primarily depends on their surface characteristics and molecular cargo. Research confirms that multiple specific proteins on exosomal surfaces mediate interactions with target cells. Notably, lysosome-associated membrane glycoprotein 2B (LAMP2B) enhances exosomal binding to neurons and their subsequent internalization, establishing its role as a key targeting protein (Qiao et al., 2023). This property provides natural targeting advantages for exosomal drug delivery. TGF-β1-induced human umbilical cord smooth muscle cell (hUCSMC)-derived exosomes exhibit effective targeting toward microglia, suppressing microglial hyperplasia and alleviating NP. Mechanistic studies reveal that urothelial cancer-associated 1 (UCA1) directly interacts with miR-95-5p to release FOXO3a expression (Mou et al., 2023). These natural targeting mechanisms enhance therapeutic efficacy while reducing impacts on non-target cells and minimizing potential side effects. Additionally, exosomes support targeting through neuronal communication functions. By binding directly to neurons and modulating their physiological states, exosomes influence pain perception and processing (Frühbeis et al., 2013). Following peripheral axonal injury, DRG sensory neurons release exosomes enriched with upregulated miR-21-5p. These exosomes are readily phagocytosed by macrophages, promoting pro-inflammatory polarization and inflammatory factor release. Intrathecal administration of miR-21 inhibitors prevents macrophage infiltration and NP development (Simeoli et al., 2017). Thus, tissue-specific exosome delivery circumvents detrimental neuron-macrophage communication, offering novel therapeutic opportunities for NP.

 Ability to cross the blood-brain barrier

BBB comprises tight junctions between endothelial cells in brain capillaries, primarily protecting the CNS from harmful substances (Lerussi et al., 2025). However, this barrier also restricts entry of many therapeutics, complicating neurological disorder treatment (Gong et al., 2025). Consequently, identifying carriers capable of crossing the BBB has become a research priority. Exosomes emerge as ideal candidates due to their natural biocompatibility and low immunogenicity. Exosomes can traverse the BBB bidirectionally between bloodstream and brain, though specific mechanisms for peripheral-to-brain migration remain incompletely elucidated (Banks et al., 2020). Exosomes primarily cross the BBB via transcytosis-transporting through intracellular compartments similarly to immune cells and pathogens-rather than paracellular routes through extracellular spaces. Post-crossing, two functional possibilities exist: complete traversal of the endothelial barrier for global brain effects (Khan et al., 2022), or sequestration within brain endothelial cells influencing these cells and triggering specific transport mechanisms (Saeedi et al., 2019; Console et al., 2019). This transmigration capability extends beyond neural stem cell (NSC)-derived exosomes. Other exosomes, including those from bone marrow mesenchymal stem cells (MSCs) and placental tissue, demonstrate similar BBB-crossing capacities. Clinically, exosomes’ penetrative ability positions them as novel neurological therapeutics. MSC-derived exosomes alleviate NP in chronic models by suppressing microglial activation and reducing neuroinflammation (Gao et al., 2023b). Moreover, exosomes show potential for delivering therapeutic molecules including miRNAs and proteins that modulate pain-processing and inflammatory pathways (Kang and Guo, 2022; Di Ianni et al., 2025).

 Low immunogenicity and high stability

Exosomal biocompatibility enables prolonged systemic circulation without immune recognition or clearance. This property permits effective therapeutic molecule delivery, enhancing efficacy while minimizing side effects. The membrane structure protects encapsulated bioactive components, maintaining stability in vivo and in vitro (Tang et al., 2021). Studies confirm prolonged exosomal circulation effectively avoids clearance by the reticuloendothelial system (Patil et al., 2020). Compared to traditional drug delivery systems, exosomes better preserve therapeutic activity and achieve higher concentrations in target tissues. Notably, surface molecules including CD47, CD24, CD44, and CD31 function as anti-phagocytic signals, helping exosomes evade phagocytic clearance by macrophages. This enhances systemic stability and bioavailability (Parada et al., 2021). As naturally derived carriers, exosomes show minimal long-term accumulation in organs compared to viral vectors, resulting in negligible systemic toxicity (Yang et al., 2015). Recent research reveals exosomes provide protection during thermal stress by transferring thermotolerance signals that help cells maintain viability under extreme conditions (Logan et al., 2024).

Exosomes constitute highly efficient miRNA delivery vehicles due to their biocompatibility, low immunogenicity, and rapid membrane fusion capacity (Bian et al., 2025). To systematically compare advantages, Table 2 details exosome-based delivery versus conventional therapies across targeting specificity, blood-brain barrier penetration, and side effects.

Comparison of exosome-based delivery systems vs. conventional therapies.

Comparison criteria Exosome-based delivery systems Conventional therapies (e.g., opioids, anticonvulsants) References
Targeting specificity Achieves tissue/cell-specific delivery via surface modifications (e.g., CD47, antibodies), minimizing off-target effects Non-specific systemic distribution, relying on passive diffusion driven by physicochemical properties (e.g., lipophilicity) Parada et al. (2021) and Yang et al. (2015)
Blood-brain barrier penetration Naturally excels in crossing the BBB or via intranasal administration for direct CNS delivery Limited penetration for most drugs, requiring high doses with increased side effects Zhao et al. (2025) and Zhou et al. (2023)
Side effects Low immunogenicity (autologous sources), no risk of addiction or respiratory depression High side-effect burden (e.g., opioid addiction, anticonvulsant-induced sedation) Arthur et al. (2025) and Leão Nunes Filho et al. (2024)
Immunomodulatory effects Carries anti-inflammatory miRNAs to suppress microglial activation and synergistically alleviate neuroinflammation Lacks direct immunomodulatory function; may exacerbate inflammation (e.g., chronic opioid use) Kaye et al. (2024) and Hua et al. (2022)
miRNA regulatory network Capable of delivering multiple miRNAs to synergistically suppress inflammation and ion channel activation Single-target action, unable to modulate complex regulatory networks Lv et al. (2017) and Su et al. (2017)
Exosome-mediated miRNA therapy: evidence and mechanisms Preclinical model evidence: validation of efficacy and mechanism Exosome-delivered miRNA targeting neuroinflammation: mechanisms underlying analgesia

Exosomal miRNAs exhibit high stability and amplification potential due to their lipid bilayer structure, enabling traversal across blood-brain or blood-spinal cord barriers to mediate analgesia in chronic pain models (Huh et al., 2017; Ding et al., 2019). In CCI rat models, miR-181c-5p expression is significantly downregulated, while intrathecal delivery of exosomal miR-181c-5p alleviates NP and neuroinflammatory responses (Zhang et al., 2022). Exosomal miRNAs operate through autocrine secretion and transport to target sites, acting on macrophages, microglia, neurons, or other tissue cells to regulate inflammatory factor secretion and oxidative stress, thereby modulating NP pathogenesis. In diabetic nephropathy (DN) mouse models, macrophage-derived EVs enriched with miR-21-5p enhance pyroptosis by upregulating A20 (a negative regulator of the NF-κB pathway). Correspondingly, intrathecal administration of anti-miR-21-5p antibodies reduces dorsal root ganglion DRG hyperalgesia and macrophage recruitment (Ding et al., 2021). Similarly, human umbilical cord mesenchymal stem cell (huc-MSC)-derived exosomes regulate microglial pyroptosis and autophagy through the miR-146a-5p/TRAF6 axis (Hua et al., 2022). Certain exosomal miRNAs alleviate neuroinflammation by inhibiting pro-inflammatory cytokine production or promoting anti-inflammatory cytokine release. For instance, human umbilical cord MSC-derived exosomes upregulate autophagy proteins LC3-II and beclin1 while blocking NLRP3 inflammasome activation via miR-146a-5p/TRAF6 signaling in the spinal dorsal horn (Hua et al., 2022). Bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) enriched with miR-23b regulate TLR4/NF-κB signaling, attenuating inflammation and improving pathological status in SCI rats (Nie and Jiang, 2021). Additionally, BMSC-derived exosomes promote miR-145-5p expression to inhibit TLR4/NF-κB pathway activation, demonstrating significant anti-inflammatory and pathway regulatory effects in both SCI rats and PC12 cells (Jiang and Zhang, 2021). These findings highlight the therapeutic value of exosomal miRNAs in controlling neuroinflammatory signaling and ameliorating neural damage.

 Synergistic protective mechanism of exosome-mediated miRNA in nerve regeneration and anti-apoptosis

Exosomes derived from Schwann cells, macrophages, and mesenchymal stem cells (MSCs) promote peripheral nerve regeneration (Sanchez et al., 2017; Marofi et al., 2017; Mead and Tomarev, 2017). Studies confirm exosomes facilitate regeneration of damaged nerves and improve motor function recovery in regenerated nerves in rat sciatic nerve compression models (Bucan et al., 2019). Exosomes enriched with the miR-17-92 cluster activate the PI3K/Akt/mTOR/GSK-3β signaling pathway by targeting PTEN, increasing neural plasticity and functional recovery (Xin et al., 2017). Specifically, skin precursor-derived Schwann cell extracellular vesicles (SKP-SC-EVs) containing miR-21-5p enhance DRG sensory neuron growth and survival through the PTEN-PI3K pathway (Cong et al., 2021). Simultaneously, miR-23b-3p promotes axonal regeneration by directly targeting Nrf1 mRNA (Xia et al., 2020). Regarding SCI models, intrathecal injection of MSC-derived exosomes significantly upregulates miR-99b-3p expression while activating microglial autophagy and alleviating mechanically induced allodynia caused by microglial activation (Gao et al., 2023a). Concurrently, exosomes from miR-126-modified MSCs reduce neuronal apoptosis while promoting functional regeneration (Huang et al., 2020), and exosomes derived from both MSCs and human neuroepithelial stem cells—enriched with miR-29b—downregulate PTEN and caspase-3 to inhibit neuronal apoptosis and confer therapeutic efficacy for SCI (Yu et al., 2019). Exosomal miR-499a-5p plays a neuroprotective role in SCI by targeting the JNK3/c-jun apoptotic pathway, reducing nerve cell apoptosis post-injury while decreasing cavity formation in lesioned areas. This mechanism promotes functional hindlimb recovery in rats through adipose-derived mesenchymal stem cell exosomes (ADSC-EXs) carrying miR-499a-5p, which reduce JNK3 expression and diminish nerve cell death after SCI (Liang et al., 2022). Adipose-derived mesenchymal stem cells (ADSCs) contain abundant neurotrophic factors, immunomodulatory factors, and angiogenic factors associated with neuronal differentiation and nerve regeneration (Harrell et al., 2022). Through miRNA transport, exosomes enhance neuronal cell activity and reduce apoptosis during early stages, thereby promoting functional recovery (see Figure 1).

Exosomal miRNA treatment for neuropathic pain. Schematic illustration of exosomal miRNA-based therapeutic strategies for neuropathic pain. Neuropathic pain models (e.g., CCI, SCI, DN) are subjected to exosomal miRNAs sourced from multiple cellular origins: nerve-resident cells (Schwann cells, microglia, neurons), mesenchymal stem cells (huc-MSCs, BMSCs, ADSCs), and immune/other lineages (macrophages, T cells, skin precursor cells). These exosomal miRNAs modulate neuropathic pain pathophysiology through dual-pronged mechanisms: ① anti-inflammatory actions (reducing neuroinflammation, promoting M2 polarization, decreasing pain sensitization); ② neuroregenerative effects (enhancing axon regeneration, suppressing neuron apoptosis, restoring motor function).

Diagram illustrating a study on exosomal miRNA treatment in neuropathic pain models. Sources of miRNA include nerve, MSC, and immune cells. A mouse model receives an injection, showing reduced neuroinflammation, enhanced M2 polarization, decreased pain, promoted axon regeneration, inhibited neuron apoptosis, and recovered motor function.

Thus, exosome-mediated miRNA transfer represents an effective therapeutic approach for NP (Table 3).

Exosomal miRNAs in preclinical models of neuropathic pain: therapeutic efficacy and mechanisms.

miRNA Model Exosome source Delivery method Target Effect Study type Objective References
miR-146a-5p↑ CIP huc-MSCs Intrathecal injection TRAF6/NLRP3↓ Mechanical allodynia and thermal hyperalgesia; reduces neuroinflammation In vitro + in vivo C57BL/6 mice Hua et al. (2022)
miR-181c-5p↑ CCI BMSC-EVs Intrathecal injection IL-6/IL-1β/TNF-α↓ Attenuates NP and neuroinflammation In vivo + in vitro SD rats Zhang et al. (2022)
miR-21-5p↓ DN Macrophage-derived Tail vein injection A20/NF-κB↓ Attenuates NP In vivo + in vitro C57BL/6 mice Ding et al. (2021)
miR-23b↑ SCI BMSC-EVs Tail vein injection TLR4/NF-κB↓ Reduces inflammation; improves spinal injury recovery In vitro + in vivo SD rats Nie and Jiang (2021)
miR-21-5p↑ PNI SKP-SCs In vitro treatment PTEN/PI3K↓ Improves neurite growth in DRG sensory neurons In vitro SD rats Cong et al. (2021)
miR-99b-3p↑ CCI hUC-MSCs Intrathecal injection PI3K/AKT/mTOR↓ Promotes autophagy; alleviates pain In vivo + in vitro SD rats Gao et al. (2023a)
miR-126↑ SCI huc-MSCs Tail vein injection SPRED1/PIK3R2↓ Promotes neurogenesis; alleviates pain In vivo + in vitro SD rats Huang et al. (2020)
miR-29b↑ SCI BMSCs Tail vein injection NF200/GAP-43↑ Promotes neural regeneration; alleviates pain In vivo + in vitro SD rats Yu et al. (2019)
miR-499a-5p↑ SCI ADSCs Tail vein injection JNK3/c-jun↓ Reduces neuronal apoptosis; improves motor function recovery In vivo + in vitro SD rats Liang et al. (2022)

BMSC, bone marrow mesenchymal stem cells; ADSC, adipose derived stem cells; hucMSC, human umbilical cord mesenchymal stem cells; SKPSCs, skin derived precursor Schwann cells; CCI, chronic constriction injury; SCI, spinal cord injury; CIP, chemotherapy induced peripheral neuropathy; DN, diabetic neuropathy; PNI, peripheral nerve injury.

 Clinical investigations

We identified clinical trials evaluating exosomes as therapeutic agents for NP (Table 4), including one published clinical trial and one ongoing registered trial (data current through June 2025). These investigations provide foundational insights into the complex mechanistic actions of exosomal miRNAs.

Clinical trials of exosome-based therapies for neuropathic pain.

Trial ID Condition Participants Exosome source Study design Intervention Phase Status Primary Findings Limitations
IRCT20200502047277N1 SCI 9 HUC-MSCs Non-randomized/open label Intrathecal injection(Single dose: 300 μg) I Completed Sensory improvement in 4/9 patients (ΔASIA Sensory Score ↑); no early/late AEs Invasive delivery; small sample (n = 9); single-center
NCT05152368 Peripheral neuropathy/trigeminal neuralgia 20 UC-MSCs Non-randomized/openlabel Intranasal instillation (single dose: 8 × 1010 particles) I Recruiting (Est. completion: January 2026) Non-invasive BBB bypass; Ongoing safety monitoring Results pending

AEs, adverse events; ASIA, American Spinal Injury Association; ΔASIA↑: exceeded minimal clinically important difference (MCID). Dose: 8 × 1010 particles = 800B exosomes (MISEV-compliant).

The completed Phase I trial IRCT20200502047277N1 (Akhlaghpasand et al., 2024) adopted a single-center design focused on safety assessment rather than efficacy evaluation. Although preliminary improvements demonstrate clinical relevance, natural disease progression complicates definitive efficacy determination. Observed sensory-motor functional enhancements in certain patients may derive from either exosomal therapeutic effects or spontaneous disease resolution. This reflects methodological constraints in current efficacy evaluation approaches, necessitating larger multicenter randomized Phase II/III trials to validate outcomes and establish the definitive therapeutic role of exosome therapy in NP. Safety monitoring revealed no severe adverse events. However, long-term biological consequences of exosomes in vivo remain undetermined. Potential concerns include sustained biological activity, immune response induction, and interference with normal cellular functions. Notably, engineered exosomal products warrant particularly rigorous risk assessment due to greater uncertainty.

Regrettably, current clinical data demonstrate: limited study accessibility, data incompleteness (e.g., pending NCT05152368 results), and recurrent methodological limitations: small cohorts, abbreviated follow-up periods, and non-blinded designs lacking placebo controls. These constraints impede comprehensive scientific assessment.

 Evolving paradigms in exosome delivery: administration routes and biomaterial innovations Comparative analysis of exosome delivery routes

Delivery routes critically influence therapeutic efficacy due to their significant impacts on exosome distribution, absorption, and functional outcomes. Different administration methods—including intrathecal injection and intranasal instillation—distinctly affect exosome biodynamics. Intrathecal injection achieves targeted delivery to injury sites, maximizing local effects while minimizing systemic side effects. Epidural injection specifically targets spinal cord tissue with reduced complication rates. Intravenous administration remains the predominant preclinical delivery route (Hassanzadeh et al., 2021), offering systemic distribution with technical simplicity and lower complication risks via caudal vein injection.

Two registered clinical studies utilize intrathecal injection and intranasal instillation. Intranasal administration leverages olfactory and trigeminal axonal pathways to bypass the blood–brain barrier, enabling direct therapeutic delivery to brain tissue. Compared to invasive approaches (intrathecal or parenchymal delivery) with infection risks, this non-invasive technique offers significant advantages. Multiple preclinical studies confirm intranasally administered exosomes effectively prevent neuronal apoptosis and improve neurological recovery (Gotoh et al., 2025).

 Engineering strategies for enhanced targeting

Exosomes exhibit unique advantages as natural drug carriers, but their clinical translation is limited by insufficient targeting specificity. For example, intravenous administration leads to rapid clearance by phagocytic organs such as the liver and spleen, significantly reducing target organ enrichment efficiency. This not only diminishes therapeutic efficacy but also raises risks of off-target toxicity. Novel exosome engineering techniques enhance delivery precision through customized miRNA loading and surface modifications (Del Pozo-Acebo et al., 2021). Research has developed genetically engineered exosomes carrying miR-21 combined with collagen-I (Col-I) scaffolds to repair SCI, demonstrating improved stability, delivery efficiency, and targeting (Liu et al., 2022).

Additionally, researchers encapsulated adipose tissue-derived mesenchymal stem cell exosomes (AD-MSC-EXs) within collagen and fibrin hydrogels (Afsartala et al., 2023), extending active retention at injury sites in SCI rat models. Gelatin sponge (Gelfoam)-loaded human umbilical cord mesenchymal stem cell exosomes (HucMSC-EXs) achieve precise delivery to SCI sites while promoting neural regeneration (Poongodi et al., 2024). Innovative tetrahedral DNA nanostructure (TDN)-based delivery systems incorporate RNase H-sensitive DNA–RNA hybrid sequences as bioswitches. Upon reaching target cells (e.g., in inflammatory or tumor microenvironments), RNase H specifically cleaves hybrid strands to trigger precise miRNA release (Li et al., 2025).

These engineering strategies can overcome biological barriers including phagocytic clearance and short half-life through surface functionalization, hydrogel sustained-release systems, and responsive nanoswitch designs, significantly enhancing spatiotemporal delivery precision.

 Clinical translation: potential and challenges Key challenges

How to address miRNA target gene complexity and functional validation bottlenecks?

How to predict exosomal miRNA therapeutic efficacy in individual patients?

What defines long-term in vivo distribution and safety profiles of therapeutic exosomes?

How to establish GMP-compliant large-scale exosome production?

How to optimize storage conditions to improve clinical feasibility?

How to reduce exosomal immunogenicity to enhance biological safety?

 Complexity of miRNA target genes and challenges in functional validation

Neuropathic pain (NP) pathogenesis involves diverse cellular and molecular mechanisms. Different NP subtypes-including chemotherapy-induced, diabetic, and traumatic NP-exhibit distinct miRNA expression profiles and functional pathways. NP models demonstrate 2,776 differentially expressed RNA molecules comprising 219 miRNAs and 2,557 mRNAs. Crucially, miRNAs regulate multiple target genes simultaneously, frequently through indirect mechanisms, significantly complicating target identification (Li et al., 2019; Golmakani et al., 2024). Current bioinformatics tools predict potential targets but lack experimental validation, undermining prediction reliability. These regulatory interactions are further complicated by cell-type specificity, microenvironmental influences, and competitive binding with non-coding RNAs (e.g., lncRNAs and circRNAs) (Mukherjee et al., 2025). miRNA regulatory networks exhibit dynamic complexity, with target specificity varying across physiological and pathological states. For instance, while miR-133a-3p overexpression attenuates microglial activation and neuroinflammation in CCI models (Jia et al., 2021; Gao et al., 2024), its upregulation conversely promotes neuroinflammation and pain development in diabetic NP (DNP) models through TRAF6 and PIAS3 protein modulation (Chang et al., 2020). Accurately interpreting miRNA functions in neuropathology requires integrated analysis of both multi-target characteristics and cell-contextual functionality. Emerging technologies-particularly single-cell RNA sequencing, NGS, and machine learning algorithms (Picchio et al., 2025)-will likely advance miRNA-target identification, accelerating NP therapeutic development.

 Scale-up: preparation, purification and quality control challenges

Exosome isolation employs diverse methods including ultracentrifugation, ultrafiltration, polymer precipitation, and immunoaffinity techniques. However, while ultracentrifugation remains the most common isolation technology, it demands specialized equipment and technical expertise while often causing damage to exosomes and functional loss (Baruah et al., 2024). Furthermore, exosome isolation is frequently contaminated by coexisting extracellular vesicles (such as microvesicles and apoptotic bodies), complicating purification processes and compromising analytical accuracy (Marjani et al., 2024). Exosomes contain diverse components including proteins, lipids, and RNAs, with biological activity closely linked to compositional integrity. Therefore, ensuring quality during preparation—particularly evaluating purity and bioactivity—represents an urgent challenge (Zhang F. et al., 2024). Currently, no standardized criteria exist to assess exosomal quality, hindering clinical translation (Sen et al., 2023; Fan et al., 2024). The International Society for Extracellular Vesicles (ISEV) aims to address these issues through its 2023 guidelines, providing technical guidance for documenting specific functional activities and procedural steps (Théry et al., 2018). Researchers are developing new technologies and standards: Microfluidics-based approaches enable improved isolation efficiency with reduced exosomal damage (Xing et al., 2025), while combined high-throughput analytical techniques and biological functional testing allow more comprehensive evaluation of exosomal quality and bioactivity (Zhang J. et al., 2024; Ishii and Tateno, 2025). These measures will enhance production consistency while ensuring clinical safety and efficacy. Future research should focus on developing efficient isolation technologies and rigorous quality control systems to achieve clinical translation of exosome-based therapies.

 Stability and biosafety of delivery systems

Delivery system stability critically determines therapeutic duration and effects in vivo. Multiple studies demonstrate that exosomes exhibit optimal stability when stored at −80°C (Levy et al., 2023), though this condition proves impractical for routine clinical application. Optimizing storage conditions is essential to ensure reliability and effectiveness in clinical settings. Current research lacks sufficient data regarding the shelf life and in vivo stability of exosomal preparations (Palakurthi et al., 2024), limiting their clinical translation. Substantial technical challenges remain unresolved, including controversial issues surrounding administration routes, injection rates, and dosage standardization (Wang et al., 2023; Batrakova and Kim, 2015). Notably, in vivo studies show no significant positive correlation between exosome dosage levels and neuroregenerative outcomes, with higher doses failing to enhance therapeutic efficacy (Zhao et al., 2020). Certain delivery systems may activate immune responses, inducing inflammation or other adverse effects that compromise treatment effectiveness (Brain et al., 2021). Some researchers have utilized cell-targeted delivery systems (CDSEMs) constructed from edible materials (Li X. et al., 2022) and delivery systems fabricated using polymer matrices and other materials, which demonstrate outstanding performance in maintaining miRNA bioactivity and reducing immune responses in vivo, significantly enhancing biosafety (Poongodi et al., 2024). The biosafety of exosomes is significantly influenced by their cellular origin and purification processes. While exosomes derived from healthy cells demonstrate favorable safety profiles in vivo, those originating from pathological conditions may cause adverse reactions (Sohrabi et al., 2022; Yamayoshi et al., 2020). Comprehensive assessment of in vivo immune responses and potential side effects is mandatory before clinical application. Strict compliance with GMP (good manufacturing practice) standards during manufacturing processes is essential to mitigate patient risks. Metabolomics can identify off-target effects and adverse drug events by detecting early signs of drug-induced liver injury, cardiotoxicity, and other complications through metabolic profile analysis (Shaman, 2024; Røikjer et al., 2024). The incomplete functional characterization of exosomes hinders accurate prediction of their long-term safety and efficacy. Although surface modification with targeting peptides significantly enhances exosomal targeting capability, potential immunogenicity of these peptides raises concerns about immune responses in humans. Developing secure and effective methods for anchoring targeting peptides to exosomes thus remains a challenging pursuit.

 Future directions

Integrating multi-omics technologies—including transcriptomics, proteomics, and metabolomics—will enable systematic elucidation exosomal miRNA mechanisms in NP. Researchers integrating genome-wide association studies (GWAS) with multi-omics data have revealed significant overlap in gene co-expression modules between NP and inflammatory pain (IP). Furthermore, integrated multi-omics analyses have identified specific miRNAs critically regulating neuroinflammation and neuronal excitability, while uncovering novel miRNA targets and signaling pathways (Ye et al., 2022). Leveraging omics technologies to select optimal donors and optimize exosome composition may consequently improve therapeutic outcomes (Lotfy et al., 2023).

Engineering exosomes through surface modifications (aptamers, antibodies, peptides) can enhance targeting precision to injured spinal cord regions and specific cell types, improving both delivery accuracy and therapeutic efficacy (Ye et al., 2023). Integrating exosomes with nanomedicine, materials science, and bioengineering could augment their therapeutic potential as delivery vehicles (Haroon et al., 2024). For instance, the RNAi-Tim3-Exo@SF hydrogel system delivers siRNA-Tim3-modified exosomes to precisely regulate Tim3 expression. This system stabilizes microtubules, promotes axonal regeneration, stimulates angiogenesis, modulates inflammatory microenvironments, and significantly improves motor function in spinal cord injury models. The key reparative mechanisms likely involve miR-155-5p within RNAi-Tim3-Exo (Dong et al., 2025). Such integrated strategies combining immunomodulation with tissue engineering may represent effective approaches for future clinical applications.

Current NP research minimally addresses large-animal models (pigs, non-human primates) in the literature. These species demonstrate greater neurological similarity to humans in axonal diameter, myelination patterns, and glial responses, enabling superior modeling of human pathological changes and pain behavior following neural injury (Karri et al., 2022). Consequently, the field urgently requires transitioning from exclusive rodent models to incorporating large-animal paradigms (e.g., porcine sciatic nerve injury models, non-human primate spinal nerve root compression models) (Ding et al., 2017). Such models better replicate human neuroanatomy and pain responses while enhancing preclinical pharmacodynamic predictability, providing robust platforms for developing targeted therapies.

Future exosome research should prioritize engineering exosomes specifically for drug delivery and clinical efficacy validation. Large-scale, multi-center studies with sufficient sample diversity and extended follow-up durations are essential to substantiate therapeutic efficacy and biosafety profiles (Figure 2).

Exosome-mediated miRNA delivery for neuropathic pain: design challenges and clinical pathways. Schematic of exosome design for neuropathic pain therapy, with challenges as the core. It maps hurdles across target gene complexity, production inefficiencies, delivery barriers, and clinical translation gaps to solutions (multi-omics, engineered targeting, regulatory pathways), illustrating how overcoming these accelerates exosome-mediated miRNA delivery to reshape NP treatment outcomes.

Diagram depicting challenges and solutions in research and production segmented into four quadrants: 1. Basic Research: Highlights multi-omics integration, AI optimization, and single-cell sequencing versus gene complexity and validation tool insufficiency.2. Scalable Production: Features technology-driven isolation and regulatory synergy against inefficiencies and lack of standards.3. Delivery Systems: Discusses engineered targeting and immune evasion against low targeting efficiency and stability issues.4. Clinical Translation: Covers large animal models and regulatory collaboration versus animal model limitations and ethical gaps.Arrows indicate the flow between challenges and innovations. Conclusion

Neuropathic pain (NP) is a refractory disorder involving multiple pathological mechanisms. It presents new therapeutic opportunities through the regulatory efficacy of miRNAs. Exosomes serve as ideal miRNA carriers due to their endogenous stability and targeted delivery advantages. Preclinical evidence confirms exosome-mediated miRNA delivery effectively alleviates NP by modulating core signaling pathways. However, clinical translation faces persistent challenges including exosomal heterogeneity, delivery efficiency bottlenecks, and complexity of personalized treatments. Addressing these requires multidisciplinary convergence of exosome engineering, biomaterials science, and clinical validation to accelerate reliable therapeutic solutions. Although current clinical implementation remains nascent, ongoing research strongly supports their translational potential.

 Author contributions

ZW: Writing – original draft, Writing – review & editing. CG: Writing – original draft, Writing – review & editing. HZ: Writing – original draft. YW: Writing – review & editing, Supervision. XZ: Validation, Supervision, Writing – original draft. JC: Funding acquisition, Resources, Project administration, Writing – review & editing. FL: Resources, Writing – review & editing, Funding acquisition, Project administration.

 Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Regional Fund Project of the National Natural Science Foundation of China (No. 82460874), the General Program of Guangxi Natural Science Foundation (2024GXNSFAA010354), the Key Research and Development Program of Guangxi (Task No. Guike AB25069271), and the General Program of Guangxi Natural Science Foundation (Task No. 2025GXNSFAA0691007).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Correction note

A correction has been made to this article. Details can be found at: 10.3389/fnmol.2025.1668038.

 Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Afsartala Z. Hadjighassem M. Shirian S. Ebrahimi-Barough S. Gholami L. Parsamanesh G. . (2023). The effect of collagen and fibrin hydrogels encapsulated with adipose tissue mesenchymal stem cell-derived exosomes for treatment of spinal cord injury in a rat model. Iran. J. Biotechnol. 21:e3505. doi: 10.30498/ijb.2023.362229.3505, PMID: 38344702 Akhlaghpasand M. Tavanaei R. Hosseinpoor M. Yazdani K. O. Soleimani A. Zoshk M. Y. . (2024). Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. Stem Cell Res Ther 15:264. doi: 10.1186/s13287-024-03868-0, PMID: 39183334 Alcántara-Montero A. Pacheco-de Vasconcelos S. R. (2022). Pharmacological approach to neuropathic pain: past, present and future. Rev. Neurol. 74, 269–279. doi: 10.33588/rn.7408.2021381, PMID: 35383875 Amescua-Garcia C. Colimon F. Guerrero C. Jreige Iskandar A. Berenguel Cook M. Bonilla P. . (2018). Most relevant neuropathic pain treatment and chronic low back pain management guidelines: a change pain Latin America advisory panel consensus. Pain Med. 19, 460–470. doi: 10.1093/pm/pnx198, PMID: 29025132 Ardeleanu V. Toma A. Pafili K. Papanas N. Motofei I. Diaconu C. C. . (2020). Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina 56:25. doi: 10.3390/medicina56010025, PMID: 31936646 Arthur J. A. Reddy A. Popat U. Halm J. Vaughan-Adams N. Myers A. . (2025). Abuse potential and analgesic efficacy of intravenous hydromorphone bolus administration among hospitalized patients with cancer pain: a double-blind, double dummy, randomized crossover trial. Cancer 131:e35723. doi: 10.1002/cncr.35723, PMID: 39865340 Bahram Sangani N. Gomes A. R. Curfs L. M. G. Reutelingsperger C. P. (2021). The role of extracellular vesicles during CNS development. Prog. Neurobiol. 205:102124. doi: 10.1016/j.pneurobio.2021.102124, PMID: 34314775 Banks W. A. Sharma P. Bullock K. M. Hansen K. M. Ludwig N. Whiteside T. L. (2020). Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation. Int. J. Mol. Sci. 21:4407. doi: 10.3390/ijms21124407, PMID: 32575812 Bao Y. Wang S. Xie Y. Jin K. Bai Y. Shan S. (2018). MiR-28-5p relieves neuropathic pain by targeting Zeb1 in CCI rat models. J. Cell. Biochem. 119, 8555–8563. doi: 10.1002/jcb.27096, PMID: 30058089 Baruah H. Sarma A. Basak D. Das M. (2024). Exosome: From biology to drug delivery. Drug Deliv. Transl. Res. 14, 1480–1516. doi: 10.1007/s13346-024-01515-y, PMID: 38252268 Batrakova E. V. Kim M. S. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control. Release 219, 396–405. doi: 10.1016/j.jconrel.2015.07.030, PMID: 26241750 Bavafa A. Izadpanahi M. Hosseini E. Hajinejad M. Abedi M. Forouzanfar F. . (2025). Exosome: an overview on enhanced biogenesis by small molecules. Naunyn Schmiedeberg’s Arch. Pharmacol. 398, 6473–6508. doi: 10.1007/s00210-024-03762-9, PMID: 39862264 Bayer K. Ahmadi S. Zeilhofer H. U. (2004). Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology 46, 743–749. doi: 10.1016/j.neuropharm.2003.11.010, PMID: 14996552 Bian X. Zhou L. Luo Z. Liu G. Hang Z. Li H. . (2025). Emerging delivery systems for enabling precision nucleic acid therapeutics. ACS Nano 19, 4039–4083. doi: 10.1021/acsnano.4c11858, PMID: 39834294 Brain D. Plant-Hately A. Heaton B. Arshad U. David C. Hedrich C. . (2021). Drug delivery systems as immunomodulators for therapy of infectious disease: relevance to COVID-19. Adv. Drug Deliv. Rev. 178:113848. doi: 10.1016/j.addr.2021.113848, PMID: 34182016 Bucan V. Vaslaitis D. Peck C. T. Strauß S. Vogt P. M. Radtke C. (2019). Effect of exosomes from rat adipose-derived mesenchymal stem cells on neurite outgrowth and sciatic nerve regeneration after crush injury. Mol. Neurobiol. 56, 1812–1824. doi: 10.1007/s12035-018-1172-z, PMID: 29931510 Cai W. Zhao Q. Shao J. Zhang J. Li L. Ren X. . (2018). MicroRNA-182 alleviates neuropathic pain by regulating Nav1.7 following spared nerve injury in rats. Sci. Rep. 8:16750. doi: 10.1038/s41598-018-34755-3, PMID: 30425258 Cai G. Zhu Y. Zhao Y. Chen J. Guo C. Wu F. . (2020). Network analysis of miRNA and mRNA changes in the prelimbic cortex of rats with chronic neuropathic pain: pointing to inflammation. Front. Genet. 11:612. doi: 10.3389/fgene.2020.00612, PMID: 32655622 Chang H. L. Wang H. C. Chunag Y. T. Chou C. W. Lin I. L. Lai C. S. . (2017). miRNA expression change in dorsal root ganglia after peripheral nerve injury. J. Mol. Neurosci. 61, 169–177. doi: 10.1007/s12031-016-0876-7, PMID: 28012097 Chang L. L. Wang H. C. Tseng K. Y. Su M. P. Wang J. Y. Chuang Y. T. . (2020). Upregulation of miR-133a-3p in the sciatic nerve contributes to neuropathic pain development. Mol. Neurobiol. 57, 3931–3942. doi: 10.1007/s12035-020-01999-y, PMID: 32632603 Chen B. Y. Sung C. W. Chen C. Cheng C. M. Lin D. P. Huang C. T. . (2019). Advances in exosomes technology. Clin. Chim. Acta 493, 14–19. doi: 10.1016/j.cca.2019.02.021, PMID: 30797770 Cohen S. P. Vase L. Hooten W. M. (2021). Chronic pain: an update on burden, best practices, and new advances. Lancet 397, 2082–2097. doi: 10.1016/S0140-6736(21)00393-7, PMID: 34062143 Cong M. Shen M. Wu X. Li Y. Wang L. He Q. . (2021). Improvement of sensory neuron growth and survival via negatively regulating PTEN by miR-21-5p-contained small extracellular vesicles from skin precursor-derived Schwann cells. Stem Cell Res Ther 12:80. doi: 10.1186/s13287-020-02125-4, PMID: 33494833 Console L. Scalise M. Indiveri C. (2019). Exosomes in inflammation and role as biomarkers. Clin. Chim. Acta 488, 165–171. doi: 10.1016/j.cca.2018.11.009, PMID: 30419221 da Silva M. D. V. Martelossi-Cebinelli G. Yaekashi K. M. Carvalho T. T. Borghi S. M. Casagrande R. . (2024). A narrative review of the dorsal root ganglia and spinal cord mechanisms of action of neuromodulation therapies in neuropathic pain. Brain Sci. 14:589. doi: 10.3390/brainsci14060589, PMID: 38928589 Del Pozo-Acebo L. Hazas M. L. L. Tomé-Carneiro J. Gil-Cabrerizo P. San-Cristobal R. Busto R. . (2021). Bovine milk-derived exosomes as a drug delivery vehicle for miRNA-based therapy. Int. J. Mol. Sci. 22:1105. doi: 10.3390/ijms22031105, PMID: 33499350 Di Ianni E. Obuchi W. Breyne K. Breakefield X. O. (2025). Extracellular vesicles for the delivery of gene therapy. Nat. Rev. Bioeng. 3, 360–373. doi: 10.1038/s44222-025-00277-7 Ding S. Q. Chen J. Wang S. N. Duan F. X. Chen Y. Q. Shi Y. J. . (2019). Identification of serum exosomal microRNAs in acute spinal cord injured rats. Exp. Biol. Med. 244, 1149–1161. doi: 10.1177/1535370219872759, PMID: 31450959 Ding X. Jing N. Shen A. Guo F. Song Y. Pan M. . (2021). MiR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20. J. Endocrinol. Investig. 44, 1175–1184. doi: 10.1007/s40618-020-01401-7, PMID: 32930981 Ding W. You Z. Shen S. Yang J. Lim G. Doheny J. T. . (2017). An improved rodent model of trigeminal neuropathic pain by unilateral chronic constriction injury of distal infraorbital nerve. J. Pain 18, 899–907. doi: 10.1016/j.jpain.2017.02.427, PMID: 28238950 Dong X. Lu Y. Hu Q. Zeng C. Zheng J. Huang J. . (2025). Engineered exosome-loaded silk fibroin composite hydrogels promote tissue repair in spinal cord injury via immune checkpoint blockade. Small:e2412170. doi: 10.1002/smll.202412170 Fan X. Zhang Y. Liu W. Shao M. Gong Y. Wang T. . (2024). A comprehensive review of engineered exosomes from the preparation strategy to therapeutic applications. Biomater. Sci. 12, 3500–3521. doi: 10.1039/D4BM00558A, PMID: 38828621 Favereaux A. Thoumine O. Bouali-Benazzouz R. Roques V. Papon M. A. Salam S. A. . (2011). Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. EMBO J. 30, 3830–3841. doi: 10.1038/emboj.2011.249, PMID: 21804529 Finnerup N. B. Kuner R. Jensen T. S. (2021). Neuropathic pain: from mechanisms to treatment. Physiol. Rev. 101, 259–301. doi: 10.1152/physrev.00045.2019, PMID: 32584191 Frühbeis C. Fröhlich D. Kuo W. P. Amphornrat J. Thilemann S. Saab A. S. . (2013). Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol. 11:e1001604. doi: 10.1371/journal.pbio.1001604, PMID: 23874151 Gao X. Gao L. F. Kong X. Q. Zhang Y. N. Jia S. Meng C. Y. (2023a). Mesenchymal stem cell-derived extracellular vesicles carrying miR-99b-3p restrain microglial activation and neuropathic pain by stimulating autophagy. Int. Immunopharmacol. 115:109695. doi: 10.1016/j.intimp.2023.109695, PMID: 36638658 Gao X. Gao L. F. Zhang Y. N. Kong X. Q. Jia S. Meng C. Y. (2023b). Huc-MSCs-derived exosomes attenuate neuropathic pain by inhibiting activation of the TLR2/MyD88/NF-κB signaling pathway in the spinal microglia by targeting Rsad2. Int. Immunopharmacol. 114:109505. doi: 10.1016/j.intimp.2022.109505, PMID: 36516531 Gao C. Yang T. Shu J. Gao X. Meng C. (2024). Overexpression of miR-133a-3p reduces microglia activation by binding to GCH1, alleviating neuroinflammation and neuropathic pain. Exp. Brain Res. 243:23. doi: 10.1007/s00221-024-06956-y, PMID: 39666013 Gaudet A. D. Mandrekar-Colucci S. Hall J. C. Sweet D. R. Schmitt P. J. Xu X. . (2016). MiR-155 deletion in mice overcomes neuron-intrinsic and neuron-extrinsic barriers to spinal cord repair. J. Neurosci. 36, 8516–8532. doi: 10.1523/JNEUROSCI.0735-16.2016, PMID: 27511021 Ghosh S. Dey A. Chakrabarti A. Bhuniya T. Indu N. Hait A. . (2024). The theragnostic advances of exosomes in managing leukaemia. J. Cell. Mol. Med. 28:e70052. doi: 10.1111/jcmm.70052, PMID: 39659020 Golmakani H. Azimian A. Golmakani E. (2024). Newly discovered functions of miRNAs in neuropathic pain: transitioning from recent discoveries to innovative underlying mechanisms. Mol. Pain 20:17448069231225845. doi: 10.1177/17448069231225845, PMID: 38148597 Gong Z. Zhou D. Wu D. Han Y. Yu H. Shen H. . (2025). Challenges and material innovations in drug delivery to central nervous system tumors. Biomaterials 319:123180. doi: 10.1016/j.biomaterials.2025.123180, PMID: 39985979 Gotoh S. Kawabori M. Yamaguchi S. Nakahara Y. Yoshie E. Konno K. . (2025). Intranasal administration of stem cell-derived exosome alleviates cognitive impairment against subarachnoid hemorrhage. Exp. Neurol. 386:115143. doi: 10.1016/j.expneurol.2025.115143, PMID: 39800250 Graner M. W. (2019). Roles of extracellular vesicles in high-grade gliomas: tiny particles with outsized influence. Annu. Rev. Genomics Hum. Genet. 20, 331–357. doi: 10.1146/annurev-genom-083118-015324, PMID: 30978305 Guo Y. Zeng J. Zhuang Y. Jiang C. Xie W. (2024). MiR-503-5p alleviates peripheral neuropathy-induced neuropathic pain in T2DM mice by regulating SEPT9 to inhibit astrocyte activation. Sci. Rep. 14:14361. doi: 10.1038/s41598-024-65096-z, PMID: 38906977 Habib A. Liang Y. Zhu N. (2023). Exosomes multifunctional roles in HIV-1: insight into the immune regulation, vaccine development and current progress in delivery system. Front. Immunol. 14:1249133. doi: 10.3389/fimmu.2023.1249133, PMID: 37965312 Han Q. Xu X. M. (2020). Neurotrophin-3-mediated locomotor recovery: a novel therapeutic strategy targeting lumbar neural circuitry after spinal cord injury. Neural Regen. Res. 15, 2241–2242. doi: 10.4103/1673-5374.284985, PMID: 32594037 Haroon K. Zheng H. Wu S. Liu Z. Tang Y. Yang G. Y. . (2024). Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury. Int. J. Pharm. 649:123656. doi: 10.1016/j.ijpharm.2023.123656, PMID: 38040392 Harrell C. R. Volarevic V. Djonov V. Volarevic A. (2022). Therapeutic potential of exosomes derived from adipose tissue-sourced mesenchymal stem cells in the treatment of neural and retinal diseases. Int. J. Mol. Sci. 23:4487. doi: 10.3390/ijms23094487, PMID: 35562878 Hassanzadeh A. Rahman H. S. Markov A. Endjun J. J. Zekiy A. O. Chartrand M. S. . (2021). Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities. Stem Cell Res Ther 12:297. doi: 10.1186/s13287-021-02378-7, PMID: 34020704 Horbay R. Hamraghani A. Ermini L. Holcik S. Beug S. T. Yeganeh B. (2022). Role of ceramides and lysosomes in extracellular vesicle biogenesis, cargo sorting and release. Int. J. Mol. Sci. 23:15317. doi: 10.3390/ijms232315317, PMID: 36499644 Hou J. Deng Q. Deng X. Zhong W. Liu S. Zhong Z. (2021). MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs). Ann. Transl. Med. 9:1433. doi: 10.21037/atm-21-3903, PMID: 34733985 Hu Y. W. Jiang J. J. Yan G. Wang R. Y. Tu G. J. (2016). MicroRNA-210 promotes sensory axon regeneration of adult mice in vivo and in vitro. Neurosci. Lett. 622, 61–66. doi: 10.1016/j.neulet.2016.04.034 Hua T. Yang M. Song H. Kong E. Deng M. Li Y. . (2022). Huc-MSCs-derived exosomes attenuate inflammatory pain by regulating microglia pyroptosis and autophagy via the miR-146a-5p/TRAF6 axis. J. Nanobiotechnology 20:324. doi: 10.1186/s12951-022-01522-6, PMID: 35836229 Huang J. H. Xu Y. Yin X. M. Lin F. Y. (2020). Exosomes derived from miR-126-modified MSCs promote angiogenesis and neurogenesis and attenuate apoptosis after spinal cord injury in rats. Neuroscience 424, 133–145. doi: 10.1016/j.neuroscience.2019.10.043, PMID: 31704348 Huh Y. Ji R. R. Chen G. (2017). Neuroinflammation, bone marrow stem cells, and chronic pain. Front. Immunol. 8:1014. doi: 10.3389/fimmu.2017.01014, PMID: 28871264 Hushmandi K. Saadat S. H. Raei M. Aref A. R. Reiter R. J. Nabavi N. . (2024). The science of exosomes: understanding their formation, capture, and role in cellular communication. Pathol. Res. Pract. 259:155388. doi: 10.1016/j.prp.2024.155388, PMID: 38850846 Ishii N. Tateno H. (2025). Preparation of small extracellular vesicles using sequential ultrafiltration with regenerated cellulose membranes of different molecular weight cutoffs: a study of morphology and size by electron microscopy. Microsc. Microanal. 31:ozae133. doi: 10.1093/mam/ozae133, PMID: 39804740 Jia S. Chen G. Liang Y. Liang X. Meng C. (2021). GCH1-regulated miRNAs are potential targets for microglial activation in neuropathic pain. Biosci. Rep. 41:BSR20210051. doi: 10.1042/BSR20210051, PMID: 34402860 Jiang Z. Zhang J. (2021). Mesenchymal stem cell-derived exosomes containing miR-145-5p reduce inflammation in spinal cord injury by regulating the TLR4/NF-κB signaling pathway. Cell Cycle 20, 993–1009. doi: 10.1080/15384101.2021.1919825, PMID: 33945431 Ju Y. Bai H. Ren L. Zhang L. (2021). The role of exosome and the ESCRT pathway on enveloped virus infection. Int. J. Mol. Sci. 22:9060. doi: 10.3390/ijms22169060, PMID: 34445766 Kang J. Guo Y. (2022). Human umbilical cord mesenchymal stem cells derived exosomes promote neurological function recovery in a rat spinal cord injury model. Neurochem. Res. 47, 1532–1540. doi: 10.1007/s11064-022-03545-9, PMID: 35132478 Kar A. N. Lee S. J. Sahoo P. K. Thames E. Yoo S. Houle J. D. . (2021). MicroRNAs 21 and 199a-3p regulate axon growth potential through modulation of Pten and mTor mRNAs. eNeuro. 8:ENEURO.0155-21.2021. doi: 10.1523/ENEURO.0155-21.2021, PMID: 34326064 Karri J. Doan J. Vangeison C. Catalanotto M. Nagpal A. S. Li S. (2022). Emerging evidence for intrathecal management of neuropathic pain following spinal cord injury. Front. Pain Res. 3:933422. doi: 10.3389/fpain.2022.933422, PMID: 35965596 Kaye A. D. Perilloux D. M. Hawkins A. M. Wester G. C. Ragaland A. R. Hebert S. V. . (2024). Tumor necrosis factor and interleukin modulators for pathologic pain states: a narrative review. Pain Ther. 13, 481–493. doi: 10.1007/s40122-024-00603-8, PMID: 38724743 Keefe K. M. Sheikh I. S. Smith G. M. (2017). Targeting neurotrophins to specific populations of neurons: NGF, BDNF, and NT-3 and their relevance for treatment of spinal cord injury. Int. J. Mol. Sci. 18:548. doi: 10.3390/ijms18030548, PMID: 28273811 Khan S. U. Khan M. I. Khan M. U. Khan N. M. Bungau S. Hassan S. S. U. (2022). Applications of extracellular vesicles in nervous system disorders: an overview of recent advances. Bioengineering 10:51. doi: 10.3390/bioengineering10010051 Kim D. M. Nimigean C. M. (2016). Voltage-gated potassium channels: a structural examination of selectivity and gating. Cold Spring Harb. Perspect. Biol. 8:a029231. doi: 10.1101/cshperspect.a029231, PMID: 27141052 Kim H. I. Park J. Zhu Y. Wang X. Han Y. Zhang D. (2024). Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp. Mol. Med. 56, 836–849. doi: 10.1038/s12276-024-01201-6, PMID: 38556545 Larios J. Mercier V. Roux A. Gruenberg J. (2020). ALIX-and ESCRT-III-dependent sorting of tetraspanins to exosomes. J. Cell Biol. 219:e201904113. doi: 10.1083/jcb.201904113 Leão Nunes Filho M. J. Barreto E. S. R. Antunes Júnior C. R. Alencar V. B. Falcão Lins-Kusterer L. E. Azi L. . (2024). Efficacy of antidepressants in the treatment of chronic nonspecific low back pain: a systematic review and meta-analysis. Pain Manag. 14, 437–451. doi: 10.1080/17581869.2024.2408215, PMID: 39377458 Leinders M. Üçeyler N. Thomann A. Sommer C. (2017). Aberrant microRNA expression in patients with painful peripheral neuropathies. J. Neurol. Sci. 380, 242–249. doi: 10.1016/j.jns.2017.07.041, PMID: 28870579 Lerussi G. Villagrasa-Araya V. Moltó-Abad M. Del Toro M. Pintos-Morell G. Seras-Franzoso J. . (2025). Extracellular vesicles as tools for crossing the blood-brain barrier to treat lysosomal storage diseases. Life 15:70. doi: 10.3390/life15010070, PMID: 39860010 Leung A. Shirvalkar P. Chen R. Kuluva J. Vaninetti M. Bermudes R. . (2020). Transcranial magnetic stimulation for pain, headache, and comorbid depression: INS-NANS expert consensus panel review and recommendation. Neuromodulation 23, 267–290. doi: 10.1111/ner.13094, PMID: 32212288 Levy D. Jeyaram A. Born L. J. Chang K. H. Abadchi S. N. Hsu A. T. W. . (2023). Impact of storage conditions and duration on function of native and cargo-loaded mesenchymal stromal cell extracellular vesicles. Cytotherapy 25, 502–509. doi: 10.1016/j.jcyt.2022.11.006, PMID: 36513574 Li H. J. Pan Y. B. Sun Z. L. Sun Y. Y. Yang X. T. Feng D. F. (2018). Inhibition of miR-21 ameliorates excessive astrocyte activation and promotes axon regeneration following optic nerve crush. Neuropharmacology 137, 33–49. doi: 10.1016/j.neuropharm.2018.04.028, PMID: 29709341 Li S. Tian T. Zhang T. Lin Y. Cai X. (2025). A bioswitchable delivery system for microRNA therapeutics based on a tetrahedral DNA nanostructure. Nat. Protoc. 20, 336–362. doi: 10.1038/s41596-024-01050-7, PMID: 39215132 Li H. Wan H. Q. Zhao H. J. Luan S. X. Zhang C. G. (2019). Identification of candidate genes and miRNAs associated with neuropathic pain induced by spared nerve injury. Int. J. Mol. Med. 44, 1205–1218. doi: 10.3892/ijmm.2019.4305, PMID: 31432094 Li X. Wei Z. Xue C. (2022). Oral cell-targeted delivery systems constructed of edible materials: advantages and challenges. Molecules 27:7991. doi: 10.3390/molecules27227991, PMID: 36432092 Li Z. Zhou Y. Li Z. (2022). NFKB1 signalling activation contributes to TRPV1 over-expression via repressing MiR-375 and MiR-455: a study on neuropathic low Back pain. Folia Biol. 68, 105–111. doi: 10.14712/fb2022068030105, PMID: 36689317 Li J. Zhu Y. Ma Z. Liu Y. Sun Z. Wu Y. (2021). miR-140 ameliorates neuropathic pain in CCI rats by targeting S1PR1. J. Recept. Signal Transduct. Res. 41, 401–407. doi: 10.1080/10799893.2020.1818091, PMID: 32924718 Liang Y. Wu J. H. Zhu J. H. Yang H. (2022). Exosomes secreted by hypoxia-pre-conditioned adipose-derived mesenchymal stem cells reduce neuronal apoptosis in rats with spinal cord injury. J. Neurotrauma 39, 701–714. doi: 10.1089/neu.2021.0290, PMID: 35018814 Liu X. Cao Y. Wang S. Liu J. Hao H. (2024). Extracellular vesicles: powerful candidates in nano-drug delivery systems. Drug Deliv. Transl. Res. 14, 295–311. doi: 10.1007/s13346-023-01411-x, PMID: 37581742 Liu Z. Y. Song Z. W. Guo S. W. He J. S. Wang S. Y. Zhu J. G. . (2019). CXCL12/CXCR4 signaling contributes to neuropathic pain via central sensitization mechanisms in a rat spinal nerve ligation model. CNS Neurosci. Ther. 25, 922–936. doi: 10.1111/cns.13128, PMID: 30955244 Liu M. Wang Y. Zhang Y. Hu D. Tang L. Zhou B. . (2025). Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct. Target. Ther. 10:73. doi: 10.1038/s41392-024-02112-8, PMID: 40059188 Liu X. Zhang L. Xu Z. Xiong X. Yu Y. Wu H. . (2022). A functionalized collagen-I scaffold delivers microRNA 21-loaded exosomes for spinal cord injury repair. Acta Biomater. 154, 385–400. doi: 10.1016/j.actbio.2022.10.027, PMID: 36270583 Logan C. J. Staton C. C. Oliver J. T. Bouffard J. Kazmirchuk T. D. D. Magi M. . (2024). Thermotolerance in S. cerevisiae as a model to study extracellular vesicle biology. J Extracell Vesicles. 13:e12431. doi: 10.1002/jev2.12431, PMID: 38711329 Lotfy A. AboQuella N. M. Wang H. (2023). Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther 14:66. doi: 10.1186/s13287-023-03287-7, PMID: 37024925 Lv F. Huang Y. Lv W. Yang L. Li F. Fan J. . (2017). MicroRNA-146a ameliorates inflammation via TRAF6/NF-κB pathway in intervertebral disc cells. Med. Sci. Monit. 23, 659–664. doi: 10.12659/MSM.898660, PMID: 28161709 Manville R. W. Papanikolaou M. Abbott G. W. (2018). Direct neurotransmitter activation of voltage-gated potassium channels. Nat. Commun. 9:1847. doi: 10.1038/s41467-018-04266-w, PMID: 29748663 Marjani A. A. Nader N. D. Aghanejad A. (2024). Exosomes as targeted diagnostic biomarkers: recent studies and trends. Life Sci. 354:122985. doi: 10.1016/j.lfs.2024.122985, PMID: 39151882 Marofi F. Vahedi G. Biglari A. Esmaeilzadeh A. Athari S. S. (2017). Mesenchymal stromal/stem cells: a new era in the cell-based targeted gene therapy of cancer. Front. Immunol. 8:1770. doi: 10.3389/fimmu.2017.01770, PMID: 29326689 Mead B. Tomarev S. (2017). Bone marrow-derived mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms. Stem Cells Transl. Med. 6, 1273–1285. doi: 10.1002/sctm.16-0428, PMID: 28198592 Meldolesi J. (2018). Exosomes and ectosomes in intercellular communication. Curr. Biol. 28, R435–R444. doi: 10.1016/j.cub.2018.01.059, PMID: 29689228 Moisset X. Pagé M. G. Pereira B. Choinière M. (2022). Pharmacological treatments of neuropathic pain: real-life comparisons using propensity score matching. Pain 163, 964–974. doi: 10.1097/j.pain.0000000000002461, PMID: 34985849 Mou C. Li Z. Liu N. Ni L. Xu Y. (2023). Low level TGF-β1-treated umbilical mesenchymal stem cells attenuates microgliosis and neuropathic pain in chronic constriction injury by exosomes/lncRNA UCA1/miR-96-5p/FOXO3a. Biochem. Biophys. Rep. 34:101477. doi: 10.1016/j.bbrep.2023.101477, PMID: 37153860 Mukherjee A. Verma A. Das T. Ghosh B. Ghosh Z. (2025). Circulating microRNAs in body fluid: “fingerprint” RNA snippets deeply impact reproductive biology. Reprod. Sci. 32, 555–574. doi: 10.1007/s43032-024-01753-y, PMID: 39658771 Nie H. Jiang Z. (2021). Bone mesenchymal stem cell-derived extracellular vesicles deliver microRNA-23b to alleviate spinal cord injury by targeting toll-like receptor TLR4 and inhibiting NF-κB pathway activation. Bioengineered 12, 8157–8172. doi: 10.1080/21655979.2021.1977562, PMID: 34663169 Ning X. J. Lu X. H. Luo J. C. Chen C. Gao Q. Li Z. Y. . (2020). Molecular mechanism of microRNA-21 promoting Schwann cell proliferation and axon regeneration during injured nerve repair. RNA Biol. 17, 1508–1519. doi: 10.1080/15476286.2020.1777767, PMID: 32507001 Nouri Z. Barfar A. Perseh S. Motasadizadeh H. Maghsoudian S. Fatahi Y. . (2024). Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases. J Nanobiotechnology. 22:463. doi: 10.1186/s12951-024-02681-4, PMID: 39095888 Palakurthi S. S. Shah B. Kapre S. Charbe N. Immanuel S. Pasham S. . (2024). A comprehensive review of challenges and advances in exosome-based drug delivery systems. Nanoscale Adv. 6, 5803–5826. doi: 10.1039/D4NA00501E, PMID: 39484149 Pan Z. Shan Q. Gu P. Wang X. M. Tai L. W. Sun M. . (2018). miRNA-23a/CXCR4 regulates neuropathic pain via directly targeting TXNIP/NLRP3 inflammasome axis. J. Neuroinflammation 15:29. doi: 10.1186/s12974-018-1073-0, PMID: 29386025 Parada N. Romero-Trujillo A. Georges N. Alcayaga-Miranda F. (2021). Camouflage strategies for therapeutic exosomes evasion from phagocytosis. J. Adv. Res. 31, 61–74. doi: 10.1016/j.jare.2021.01.001, PMID: 34194832 Patil S. M. Sawant S. S. Kunda N. K. (2020). Exosomes as drug delivery systems: a brief overview and progress update. Eur. J. Pharm. Biopharm. 154, 259–269. doi: 10.1016/j.ejpb.2020.07.026, PMID: 32717385 Pedder J. H. Sonabend A. M. Cearns M. D. Michael B. D. Zakaria R. Heimberger A. B. . (2025). Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease. Lancet Neurol. 24, 246–260. doi: 10.1016/S1474-4422(24)00476-9, PMID: 39862873 Peng C. Li L. Zhang M. D. Bengtsson Gonzales C. Parisien M. Belfer I. . (2017). MiR-183 cluster scales mechanical pain sensitivity by regulating basal and neuropathic pain genes. Science 356, 1168–1171. doi: 10.1126/science.aam7671, PMID: 28572455 Picchio V. Pontecorvi V. Dhori X. Bordin A. Floris E. Cozzolino C. . (2025). The emerging role of artificial intelligence applied to exosome analysis: from cancer biology to other biomedical fields. Life Sci. 375:123752. doi: 10.1016/j.lfs.2025.123752, PMID: 40409585 Poongodi R. Yang T. H. Huang Y. H. Yang K. D. Chen H. Z. Chu T. Y. . (2024). Stem cell exosome-loaded Gelfoam improves locomotor dysfunction and neuropathic pain in a rat model of spinal cord injury. Stem Cell Res Ther 15:143. doi: 10.1186/s13287-024-03758-5, PMID: 38764049 Qi R. Cao J. Sun Y. Li Y. Huang Z. Jiang D. . (2022). Histone methylation-mediated microRNA-32-5p down-regulation in sensory neurons regulates pain behaviors via targeting Cav3.2 channels. Proc. Natl. Acad. Sci. U.S.A. 119:e2117209119. doi: 10.1073/pnas.2117209119, PMID: 35353623 Qiao L. Hu J. Qiu X. Wang C. Peng J. Zhang C. . (2023). LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles. Autophagy 19, 2837–2852. doi: 10.1080/15548627.2023.2235196, PMID: 37469132 Ren X. Xu R. Xu C. Su J. (2024). Harnessing exosomes for targeted therapy: strategy and application. Biomater. Transl. 5, 46–58. doi: 10.12336/biomatertransl.2024.01.005, PMID: 39220669 Røikjer J. Borbjerg M. K. Andresen T. Giordano R. Hviid C. V. B. Mørch C. D. . (2024). Diabetic peripheral neuropathy: emerging treatments of neuropathic pain and novel diagnostic methods. J. Diabetes Sci. Technol.:19322968241279553. doi: 10.1177/19322968241279553 Saeedi S. Israel S. Nagy C. Turecki G. (2019). The emerging role of exosomes in mental disorders. Transl. Psychiatry 9:122. doi: 10.1038/s41398-019-0459-9, PMID: 30923321 Sakai A. Saitow F. Maruyama M. Miyake N. Miyake K. Shimada T. . (2017). MicroRNA cluster miR-17-92 regulates multiple functionally related voltage-gated potassium channels in chronic neuropathic pain. Nat. Commun. 8:16079. doi: 10.1038/ncomms16079, PMID: 28677679 Sakai A. Saitow F. Miyake N. Miyake K. Shimada T. Suzuki H. (2013). Mir-7a alleviates the maintenance of neuropathic pain through regulation of neuronal excitability. Brain 136, 2738–2750. doi: 10.1093/brain/awt191, PMID: 23861446 Sanchez D. N. R. Bertanha M. Fernandes T. D. Resende L. A. L. Deffune E. Amorim R. M. (2017). Effects of canine and murine mesenchymal stromal cell transplantation on peripheral nerve regeneration. Int. J. Stem Cells 10, 83–92. doi: 10.15283/ijsc16037, PMID: 28446003 Savelieff M. G. Elafros M. A. Viswanathan V. Jensen T. S. Bennett D. L. Feldman E. L. (2025). The global and regional burden of diabetic peripheral neuropathy. Nat. Rev. Neurol. 21, 17–31. doi: 10.1038/s41582-024-01041-y Sen S. Xavier J. Kumar N. Ahmad M. Z. Ranjan O. P. (2023). Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech 13:101. doi: 10.1007/s13205-023-03521-2, PMID: 36860361 Shaman J. A. (2024). The future of pharmacogenomics: integrating epigenetics, nutrigenomics, and beyond. J. Pers. Med. 14:1121. doi: 10.3390/jpm14121121, PMID: 39728034 Shen W. S. Li C. F. Zhou Z. S. Zhai N. N. Pan L. P. (2020). MicroRNA-204 silencing relieves pain of cervical spondylotic radiculopathy by targeting GDNF. Gene Ther. 27, 254–265. doi: 10.1038/s41434-019-0114-3, PMID: 31819204 Shen F. Zheng H. Zhou L. Li W. Zhang Y. Xu X. (2019). LINC00657 expedites neuropathic pain development by modulating miR-136/ZEB1 axis in a rat model. J. Cell. Biochem. 120, 1000–1010. doi: 10.1002/jcb.27466, PMID: 30203524 Shityakov S. Nagai M. Ergün S. Braunger B. M. Förster C. Y. (2022). The protective effects of neurotrophins and microRNA in diabetic retinopathy, nephropathy and heart failure via regulating endothelial function. Biomol. Ther. 12:1113. doi: 10.3390/biom12081113, PMID: 36009007 Simeoli R. Montague K. Jones H. R. Castaldi L. Chambers D. Kelleher J. H. . (2017). Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma. Nat. Commun. 8:1778. doi: 10.1038/s41467-017-01841-5, PMID: 29176651 Sohrabi B. Dayeri B. Zahedi E. Khoshbakht S. Nezamabadi Pour N. Ranjbar H. . (2022). Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy. Cancer Gene Ther. 29, 1105–1116. doi: 10.1038/s41417-022-00427-8, PMID: 35082400 Su S. Shao J. Zhao Q. Ren X. Cai W. Li L. . (2017). MiR-30b attenuates neuropathic pain by regulating voltage-gated sodium channel Nav1.3 in rats. Front. Mol. Neurosci. 10:126. doi: 10.3389/fnmol.2017.00126, PMID: 28529474 Sun L. Xia R. Jiang J. Wen T. Huang Z. Qian R. . (2021). MicroRNA-96 is required to prevent allodynia by repressing voltage-gated sodium channels in spinal cord. Prog. Neurobiol. 202:102024. doi: 10.1016/j.pneurobio.2021.102024, PMID: 33636225 Sun W. Zhang L. Li R. (2017). Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor. Neurosci. Lett. 646, 68–74. doi: 10.1016/j.neulet.2016.12.047, PMID: 28130187 Tang X. H. Guo T. Gao X. Y. Wu X. L. Xing X. F. Ji J. F. . (2021). Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol. Cancer 20:99. doi: 10.1186/s12943-021-01396-6, PMID: 34330299 Tavares-Ferreira D. Lawless N. Bird E. V. Atkins S. Collier D. Sher E. . (2019). Correlation of miRNA expression with intensity of neuropathic pain in man. Mol. Pain 15:1744806919860323. doi: 10.1177/1744806919860323, PMID: 31218919 Théry C. Witwer K. W. Aikawa E. Alcaraz M. J. Anderson J. D. Andriantsitohaina R. . (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell Vesicles. 7:1535750. doi: 10.1080/20013078.2018.1535750, PMID: 30637094 van Battum E. Y. Verhagen M. G. Vangoor V. R. Fujita Y. Derijck A. O’Duibhir E. . (2018). An image-based miRNA screen identifies miRNA-135s as regulators of CNS axon growth and regeneration by targeting Krüppel-like factor 4. J. Neurosci. 38, 613–630. doi: 10.1523/JNEUROSCI.0662-17.2017 Vranken J. H. (2012). Elucidation of pathophysiology and treatment of neuropathic pain. Cent. Nerv. Syst. Agents Med. Chem. 12, 304–314. doi: 10.2174/187152412803760645 Vučemilović A. (2024). Exosomes: intriguing mediators of intercellular communication in the organism’s response to noxious agents. Arh. Hig. Rada Toksikol. 75, 228–239. doi: 10.2478/aiht-2024-75-3923, PMID: 39718095 Wang H. Li Q. Zou J. Shu J. Zhang A. Zhang H. . (2024). Mapping the research landscape of microRNAs in pain: a comprehensive bibliometric analysis. Front. Mol. Neurosci. 17:1493822. doi: 10.3389/fnmol.2024.1493822, PMID: 39776492 Wang Z. Liu F. Wei M. Qiu Y. Ma C. Shen L. . (2018). Chronic constriction injury-induced microRNA-146a-5p alleviates neuropathic pain through suppression of IRAK1/TRAF6 signaling pathway. J. Neuroinflammation 15:179. doi: 10.1186/s12974-018-1215-4, PMID: 29885668 Wang Y. Wu X. (2024). New perspectives and prospects of microRNA delivery in diabetic wound healing. Mol. Pharmacol. 106, 84–91. doi: 10.1124/molpharm.124.000899, PMID: 39019572 Wang C. Xu M. Fan Q. Li C. Zhou X. (2023). Therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases. Asian J. Pharm. Sci. 18:100772. doi: 10.1016/j.ajps.2022.100772, PMID: 36896446 Wilkerson J. L. Jiang J. Felix J. S. Bray J. K. da Silva L. Gharaibeh R. Z. . (2020). Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain. Neurosci. Lett. 731:135029. doi: 10.1016/j.neulet.2020.135029, PMID: 32380144 Wu H. Zhu L. Geng X. Guo X. Wang T. Xu J. . (2025). miR-363-5p protects from neuropathic pain in chronic constriction injury (CCI) rat models and regulates Schwann cell injury via negatively modulating SERPING1. Neurol. Res. 47, 35–43. doi: 10.1080/01616412.2024.2438613, PMID: 39663908 Xia B. Gao J. Li S. Huang L. Zhu L. Ma T. . (2020). Mechanical stimulation of Schwann cells promote peripheral nerve regeneration via extracellular vesicle-mediated transfer of microRNA 23b-3p. Theranostics 10, 8974–8995. doi: 10.7150/thno.44912, PMID: 32802175 Xin H. Katakowski M. Wang F. Qian J. Y. Liu X. S. Ali M. M. . (2017). MicroRNA cluster miR-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. Stroke 48, 747–753. doi: 10.1161/STROKEAHA.116.015204, PMID: 28232590 Xing Y. H. Ren X. S. Li D. H. Liu L. (2025). Exosome separation and analysis based on microfluidics technology and its clinical applications. Se Pu 43, 455–471. doi: 10.3724/SP.J.1123.2024.10032, PMID: 40331610 Yamayoshi A. Oyama S. Kishimoto Y. Konishi R. Yamamoto T. Kobori A. . (2020). Development of antibody-oligonucleotide complexes for targeting exosomal MicroRNA. Pharmaceutics 12:545. doi: 10.3390/pharmaceutics12060545, PMID: 32545479 Yan X. T. Ji L. J. Wang Z. Wu X. Wang Q. Sun S. . (2017). MicroRNA-93 alleviates neuropathic pain through targeting signal transducer and activator of transcription 3. Int. Immunopharmacol. 46, 156–162. doi: 10.1016/j.intimp.2017.01.027, PMID: 28284149 Yan X. T. Zhao Y. Cheng X. L. He X. H. Wang Y. Zheng W. Z. . (2018). Inhibition of miR-200b/miR-429 contributes to neuropathic pain development through targeting zinc finger E box binding protein-1. J. Cell. Physiol. 233, 4815–4824. doi: 10.1002/jcp.26284, PMID: 29150958 Yanagawa K. Kuma A. Hamasaki M. Kita S. Yamamuro T. Nishino K. . (2024). The Rubicon-WIPI axis regulates exosome biogenesis during ageing. Nat. Cell Biol. 26, 1558–1570. doi: 10.1038/s41556-024-01481-0, PMID: 39174742 Yang K. Fu W. Deng M. Li X. Wu M. Wang Y. (2024). The sphingolipids change in exosomes from cancer patients and association between exosome release and sphingolipids level based on a pseudotargeted lipidomics method. Anal. Chim. Acta 1305:342527. doi: 10.1016/j.aca.2024.342527, PMID: 38677835 Yang X. Huang X. Lu W. Yan F. Ye Y. Wang L. . (2023). Transcriptome profiling of miRNA-mRNA interactions and associated mechanisms in chemotherapy-induced neuropathic pain. Mol. Neurobiol. 60, 5672–5690. doi: 10.1007/s12035-023-03398-5, PMID: 37332017 Yang T. Martin P. Fogarty B. Brown A. Schurman K. Phipps R. . (2015). Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm. Res. 32, 2003–2014. doi: 10.1007/s11095-014-1593-y, PMID: 25609010 Yang R. Wang Q. Q. Feng Y. Li X. H. Li G. X. She F. L. . (2023). Over-expression of miR-3584-5p represses Nav1.8 channel aggravating neuropathic pain caused by chronic constriction injury. Mol. Neurobiol. 60, 5237–5255. doi: 10.1007/s12035-023-03394-9, PMID: 37280408 Yang S. Zhu H. Jin H. Wang K. Song J. Sun N. . (2025). Bio-orthogonal-labeled exosomes reveals specific distribution in vivo and provides potential application in ARDS therapy. Biomaterials 319:123208. doi: 10.1016/j.biomaterials.2025.123208, PMID: 40023928 Yao L. Zi G. He M. Xu Y. Wang L. Peng B. (2025). Asparagine endopeptidase regulates lysosome homeostasis via modulating endomembrane phosphoinositide composition. Cell Death Dis. 15:883. doi: 10.1038/s41419-024-07187-3, PMID: 39743643 Ye F. Du L. Huang W. Wang S. (2022). Shared genetic regulatory networks contribute to neuropathic and inflammatory pain: multi-omics systems analysis. Biomol. Ther. 12:1454. doi: 10.3390/biom12101454, PMID: 36291662 Ye H. Wang F. Xu G. Shu F. Fan K. Wang D. (2023). Advancements in engineered exosomes for wound repair: current research and future perspectives. Front. Bioeng. Biotechnol. 11:1301362. doi: 10.3389/fbioe.2023.1301362, PMID: 38033824 Yu T. Zhao C. Hou S. Zhou W. Wang B. Chen Y. (2019). Exosomes secreted from miRNA-29b-modified mesenchymal stem cells repaired spinal cord injury in rats. Braz. J. Med. Biol. Res. 52:e8735. doi: 10.1590/1414-431x20198735, PMID: 31826179 Zarezadeh Mehrabadi A. Aghamohamadi N. Khoshmirsafa M. Aghamajidi A. Pilehforoshha M. Massoumi R. . (2022). The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions. Immunology 166, 38–46. doi: 10.1111/imm.13462, PMID: 35231129 Zhang H. Chen H. (2021). TRPA1 involved in miR-141-5p-alleviated neuropathic pain induced by oxaliplatin. Neuroreport 32, 284–290. doi: 10.1097/WNR.0000000000001589, PMID: 33534373 Zhang X. Guo H. Xie A. Liao O. Ju F. Zhou Y. (2020a). MicroRNA-144 relieves chronic constriction injury-induced neuropathic pain via targeting RASA1. Biotechnol. Appl. Biochem. 67, 294–302. doi: 10.1002/bab.1854, PMID: 31737949 Zhang D. Lee H. Zhu Z. Minhas J. K. Jin Y. (2017). Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 312, L110–L1121. doi: 10.1152/ajplung.00423.2016, PMID: 27881406 Zhang J. Li K. Gao L. Zhu P. Shu L. Cai L. . (2024). Glucose metabolism disorder related to follicular fluid exosomal miR-122-5p in cumulus cells of endometriosis patients. Reproduction 168:e240028. doi: 10.1530/REP-24-0028, PMID: 39042724 Zhang K. Li P. Jia Y. Liu M. Jiang J. (2023). Concise review: current understanding of extracellular vesicles to treat neuropathic pain. Front. Aging Neurosci. 15:1131536. doi: 10.3389/fnagi.2023.1131536, PMID: 36936505 Zhang Y. Liu H. L. An L. J. Li L. Wei M. Ge D. J. . (2019). miR-124-3p attenuates neuropathic pain induced by chronic sciatic nerve injury in rats via targeting EZH2. J. Cell. Biochem. 120, 5747–5755. doi: 10.1002/jcb.27861, PMID: 30390343 Zhang J. Rong L. Shao J. Zhang Y. Liu Y. Zhao S. . (2021). Epigenetic restoration of voltage-gated potassium channel Kv1.2 alleviates nerve injury-induced neuropathic pain. J. Neurochem. 156, 367–378. doi: 10.1111/jnc.15117, PMID: 32621322 Zhang Y. U. Ye G. Zhao J. Chen Y. Kong L. Sheng C. . (2022). Exosomes carried miR-181c-5p alleviates neuropathic pain in CCI rat models. An. Acad. Bras. Cienc. 94:e20210564. doi: 10.1590/0001-3765202220210564 Zhang X. Zhang Y. Cai W. Liu Y. Liu H. Zhang Z. . (2020b). MicroRNA-128-3p alleviates neuropathic pain through targeting ZEB1. Neurosci. Lett. 729:134946. doi: 10.1016/j.neulet.2020.134946, PMID: 32278027 Zhang F. Zhang L. Yu H. (2024). Potential druggability of mesenchymal stem/stromal cell-derived exosomes. Curr. Stem Cell Res. Ther. 19, 1195–1209. doi: 10.2174/011574888X311270240319084835, PMID: 38523514 Zhao J. Ding Y. He R. Huang K. Liu L. Jiang C. . (2020). Dose-effect relationship and molecular mechanism by which BMSC-derived exosomes promote peripheral nerve regeneration after crush injury. Stem Cell Res Ther 11:360. doi: 10.1186/s13287-020-01872-8, PMID: 32811548 Zhao M. Li Q. Chai Y. Rong R. He L. Zhang Y. . (2025). An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma. J. Nanobiotechnology. 23:173. doi: 10.1186/s12951-025-03238-9, PMID: 40045315 Zhong L. Xiao W. Wang F. Liu J. Zhi L. J. (2019). miR-21-5p inhibits neuropathic pain development via directly targeting C-C motif ligand 1 and tissue inhibitor of metalloproteinase-3. J. Cell. Biochem. 120, 16614–16623. doi: 10.1002/jcb.28920, PMID: 31161659 Zhou X. Deng X. Liu M. He M. Long W. Xu Z. . (2023). Intranasal delivery of BDNF-loaded small extracellular vesicles for cerebral ischemia therapy. J. Control. Release 357, 1–19. doi: 10.1016/j.jconrel.2023.03.033, PMID: 36958402 Glossary Key terminology miRNA

microRNA

 NP

Neuropathic pain

 Cells & exosomes ADSC-EXs

Adipose-derived mesenchymal stem cell exosomes

 BMSC-EVs

Bone marrow mesenchymal stem cell-derived extracellular vesicles

 DRG

Dorsal root ganglion

 EVs

Extracellular vesicles

 huc-MSCs

Human umbilical cord mesenchymal stem cells

 MSC

Mesenchymal stem cell

 SKP-SCs

Skin-derived precursor Schwann cells

 Clinical terms AEs

Adverse events

 ASIA

American Spinal Injury Association

 BBB

Blood-brain barrier

 CNS

Central nervous system

 GMP

Good manufacturing practice

 MCID

Minimal clinically important difference

 Disease models CCI

Chronic constriction injury

 CIP

Chemotherapy-induced peripheral neuropathy

 DPN

Diabetic peripheral neuropathy

 ONI

Optic nerve injury

 OXA

Oxaliplatin

 pSNL

Partial sciatic nerve ligation

 SCI

Spinal cord injury

 SNI

Spared nerve injury

 SNL

Spinal nerve ligation

 TN

Trigeminal neuralgia

 Molecular pathways Akt

Protein kinase B

 BDNF

Brain-derived neurotrophic factor

 EFNA3

Ephrin-A3

 GDNF

Glial cell-derived neurotrophic factor

 GAP-43

Growth-associated protein 43

 IRAK1

Interleukin-1 receptor-associated kinase 1

 JNK3

c-Jun N-terminal kinase 3

 KLF4

Krüppel-like factor 4

 LAMP2B

Lysosome-associated membrane protein 2B

 MAPK

Mitogen-activated protein kinase

 mTOR

Mechanistic target of rapamycin

 NF-κB

Nuclear factor kappa-light-chain-enhancer of activated B cells

 NGF

Nerve growth factor

 NLRP3

NLR Family pyrin domain containing 3

 NMDA

N-Methyl-D-aspartate receptor

 NT-3

Neurotrophin-3

 PI3K

Phosphoinositide 3-kinase

 PTEN

Phosphatase and tensin homolog

 Rab27a/b

Ras-related protein Rab-27A/B

 SEPT9

Septin 9

 STAT3

Signal transducer and activator of transcription 3

 TGF-β1

Transforming growth factor beta 1

 TLR4

Toll-like receptor 4

 TRAF6

TNF receptor-associated factor 6

 TRPA1

Transient receptor potential ankyrin 1

 TRPV1

Transient receptor potential vanilloid 1

 TXNIP

Thioredoxin-interacting protein

 ZEB1

Zinc Finger E-box binding homeobox 1

 Other key terminology DAMPs

Damage-associated molecular patterns

 lncRNA

Long non-coding rna

 TDN

Tetrahedral DNA nanostructure

 UCA1

Urothelial cancer-associated 1

 Technical methods ESCRT

Endosomal sorting complexes required for transport

 GWAS

Genome-wide association study

 ISEV

International Society for Extracellular Vesicles

 MISEV

Minimal information for EV studies

 NGS

Next-generation sequencing

 SCS

Spinal cord stimulation

 TENS

Transcutaneous electrical nerve stimulation